Ligand-based drug design : I. conformational studies of GBR 12909 analogs as cocaine antagonists; II. 3d-QSAR studies of salvinorin a analogs as kappa opioid agonists by Pandit, Deepangi
New Jersey Institute of Technology 
Digital Commons @ NJIT 
Dissertations Electronic Theses and Dissertations 
Spring 5-31-2007 
Ligand-based drug design : I. conformational studies of GBR 
12909 analogs as cocaine antagonists; II. 3d-QSAR studies of 
salvinorin a analogs as kappa opioid agonists 
Deepangi Pandit 
New Jersey Institute of Technology 
Follow this and additional works at: https://digitalcommons.njit.edu/dissertations 
 Part of the Chemistry Commons 
Recommended Citation 
Pandit, Deepangi, "Ligand-based drug design : I. conformational studies of GBR 12909 analogs as cocaine 
antagonists; II. 3d-QSAR studies of salvinorin a analogs as kappa opioid agonists" (2007). Dissertations. 
820. 
https://digitalcommons.njit.edu/dissertations/820 
This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at Digital 
Commons @ NJIT. It has been accepted for inclusion in Dissertations by an authorized administrator of Digital 
Commons @ NJIT. For more information, please contact digitalcommons@njit.edu. 
 
Copyright Warning & Restrictions 
 
 
The copyright law of the United States (Title 17, United 
States Code) governs the making of photocopies or other 
reproductions of copyrighted material. 
 
Under certain conditions specified in the law, libraries and 
archives are authorized to furnish a photocopy or other 
reproduction. One of these specified conditions is that the 
photocopy or reproduction is not to be “used for any 
purpose other than private study, scholarship, or research.” 
If a, user makes a request for, or later uses, a photocopy or 
reproduction for purposes in excess of “fair use” that user 
may be liable for copyright infringement, 
 
This institution reserves the right to refuse to accept a 
copying order if, in its judgment, fulfillment of the order 
would involve violation of copyright law. 
 
Please Note:  The author retains the copyright while the 
New Jersey Institute of Technology reserves the right to 
distribute this thesis or dissertation 
 
 
Printing note: If you do not wish to print this page, then select  
“Pages from: first page # to: last page #”  on the print dialog screen 
 
The Van Houten library has removed some of
the personal information and all signatures from
the approval page and biographical sketches of
theses and dissertations in order to protect the
identity of NJIT graduates and faculty.
ABSTRACT
LIGAND-BASED DRUG DESIGN: I. CONFORMATIONAL STUDIES OF
GBR 12909 ANALOGS AS COCAINE ANTAGONISTS; II. 3D-QSAR
STUDIES OF SALVINORIN A ANALOGS AS εΑΡΡΑ OPIOID AGONISTS
by
Deepangi Pandit
Ligand-based drug design (LBDD) techniques are applied when the structure of the
receptor is unknown but when a series of compounds or ligands have been identified
that show the biological activity of the interest. Generally, availability of a series of
compounds with high activity, with no activity, and also with a range of intermediate
activities for the desired biological target is required. It is common that structures of
membrane-bound proteins (for example, monoamine transporter proteins and opioid
receptor proteins) are unknown as these proteins are notoriously difficult to crystallize.
In Part I of this study, analogs of the flexible dopamine reuptake inhibitor, GBR
12909, may have potential usefulness in the treatment of cocaine abuse. As a first step
in the 3D-QSAR modeling of the dopamine transporter (DAT)/serotonin transporter
(SERI) selectivity of these compounds, conformational analysis of a piperazine and
related piperidine analog of GBR12909 is performed. These analogs have eight
rotatable bonds and are somewhat easier to deal with computationally than the parent
compound. Ensembles of conformers consisting of local minima on the potential energy
surface of the molecule were generated in the vacuum phase and implicit solvent (also
known as continuum solvent) by random search conformational analysis using the
molecular mechanics methods and the Tripos and MMFF94 force fields. These
conformer populations were classified by relative energy, molecular shape, and their
behavior in 2D torsional angle space in order to evaluate their sensitivity to the choice
of charges and force field. Some differences were noted in the conformer populations
due to differences in the treatment of the tertiary amine nitrogen and ether oxygen atom
types by the force fields.
In Part II of this study, 3D-QSAR studies of salvinorin A analogs as kappa opioid
(κ) receptor agonists were performed. Salvinorin A is a naturally-occurring diterpene
from the plant Salvia divinorum which activates the kappa opioid receptor (KOR)
selectively and potently. It is the only known natural non-nitrogenous agent active at the
human KOR. Salvinorin A may represent a novel lead compound with possible
potential in the treatment of addiction and pain. The primary aim of the current study
was to develop Comparative Molecular Field Analysis (CoMFA) models to clarify the
correlation between the molecular features of the 2-position analogs of salvinorin A and
their KOR binding affinity. The final, stable CoMFA model has predictivity given by q 2
of 0.62 and fit given by r2 of 0.86. The steric and electrostatic contributions were 47%
and 53%, respectively. The CoMFA contour map indicated that the presence of a
negative environment and steric region near the 2-position would lead to improved
binding affinity at the KOR. Novel salvinorin A analogs with improved binding affinity
were predicted based on the stable and predictive CoMFA model. Novel analogs were
synthesized by Dr. Thomas Prisinzano of the University of Iowa and preliminary
biological results are available from the Rothman laboratory at the National Institute on
Drug Abuse. These novel analogs appear to be KOR selective.
LIGAND-BASED DRUG DESIGN: I. CONFORMATIONAL STUDIES OF
GBR 12909 ANALOGS AS COCAINE ANTAGONISTS; II. 3D-QSAR STUDIES
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PART I
CONFORMATIONAL STUDIES OF GBR 12909
ANALOGS AS COCAINE ANATAGONISTS
CHAPTER 1
INTRODUCTION
Currently there are no Food and Drug Administration approved therapeutic agents
available for the treatment of cocaine abuse or for the prevention of its relapse. It is
accepted that addiction is caused by disorders of the brain, with specific neurobiological,
molecular and behavioral characteristics that have environmental, drug-induced and
genetic determinants of vulnerability. 1 Cocaine addiction may be compared to a chronic
illness like diabetes which may be managed but not always cured. 2 Since the proposal of
the "dopamine hypothesis", various compounds have been pursued as possible cocaine
abuse therapeutics. 3 ' 4 The hypothesis states that cocaine induces a sense of excitement in
the user primarily by blocking the reuptake of the neurotransmitter dopamine (DA) at the
dopamine transporter protein (DAT) (Figure 1.1). The dopamine hypothesis is able to
explain some aspects of stimulant addiction, but other neurochemical mechanisms appear
to be more complicated. Recently the analysis of the (DAT)-, serotonin transporter
(SERI)-, and norepinephrine transporter (NET)- knockout (KO) mice has indicated that
the SERI and the NET also play a role in the pharmacological effects of cocaine. 5-7 All
three monoamines (dopamine, serotonin and norepinephrine) have specific transporter
proteins for their transport, but it has been observed that either the DAT or NET can
transport both dopamine and norepinephrine. It is now well known that cocaine primarily
acts on the dopaminergic system, with some effect on the serotonergic,
norepinephrinergic, and opioid systems. Cocaine affects dopamine receptors in an
indirect fashion by increasing dopamine levels in the synaptic cleft as the result of
1
2
Figure 1.1 Schematic representation of effect of cocaine on DAT.
[Source: National Institutes of Health (ΝΙΗ) Publication Number 99-4342 Cocaine and Addiction, May
1999]
inhibition of dopamine reuptake through dopamine transporters. $ The interplay between
these systems of monoamine transporter proteins and receptor proteins during cocaine
addiction is just beginning to be deciphered. These systems in turn have a profound effect
on numerous cellular and molecular targets, including glutamate transmission, GAGA
transmission and opioid receptors. These factors play an important role in drug addiction
which can be divided into three stages: binge/intoxication, withdrawal/negative affect and
preoccupation/anticipation.
The primary focus of drug development for the treatment of cocaine addiction has
been the design of ligands to prevent the binding of cocaine to the DAT 3 but recently
other biological targets also have been explored. 1 DAT ligands are structurally diverse
and include tropane, benztropine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-
phenylpropyl) piperazine (GBR 12909)-analogs, methylphenidate, mazindol and
3
phencyclidine analogs. 9-13 It is believed that an agent that binds to the DAT with high
affinity but slow dissociation rate, preventing cocaine from binding while allowing the
reuptake of dopamine, would be able to neutralize the effect of cocaine. GBR 12909 has
a unique pharmacological profile which may lend it potential in the treatment of cocaine
addiction. Compared to cocaine, it has a higher binding affinity for the DAT and a a
slower dissociation rate from the DAT. It has also successfully completed Phase I clinical
trials. Our collaborators, the Rice and Rothman groups at the National Institutes of
Health, have synthesized and tested the binding affinity of hundreds of GBR 12909
analogs in search of an agent with high selectivity for the DAT, compared to the SERI
and NET. 13 Of course, it is clear from the literature that addiction is a complex and
complicated phenomenon but GBR 12909 is being used as a tool to test the dopamine
hypothesis of stimulant addiction in humans. However, other therapeutic targets are being
investigated to determine their role in the treatment and management of stimulant
addiction. 13
1.1 Neurotransmitter Transporter Genes" a
The DAT, SERI and NET are the members of the sodium- and chloride-dependent
neurotransmitter transporter family solute carrier 6 (SLC6). The SLC6 family transports
solutes across cell plasma membranes at the same time as it co-transports sodium and
chloride down their electrochemical gradients. These transporters have generally 12
transmembrane domains, with cytoplasmic N- and C-terminal tails with glycosylation
sites present between transmembranes (TM) 3 and 4. The DAT, SERI and NET have
620, 630 and 619 amino acid residues, respectively. Proteins of this family are regulated
4
by protein kinases and via protein-protein interactions. Family members also include the
transporters for y-amino butyric acid (GAGA), glycine, betaine, taurine, proline and
creatine. The transporter proteins of this family have high sequence homology. For
example, compared to the DAT, the sequence identity of the other transporters is as
follows: NET 67%, serotonin 49%, GAGA 45%, glycine 41%, betaine 44%, taurine 42%,
proline 44% and creatine 43%. These transporters regulate signaling among neurons in
the central and peripheral nervous systems. Below, regulation of the SLC6Α3 member
(DAT) of the SLC6 transporter proteins expressed in neural cells is briefly discussed.
DAT Gene and Regulation
SLC6Α3: DAT 	 The human DAT gene (SLC6Α3) is localized 15 ' 16 to chromosome
5p15.3. It spans about 65 kilo base pairs and is divided into 15 exons with no evidence of
RNA splice variants. Various approaches have been implemented to map the substrate
interaction site of the DAT and its translocation pathway; however a clear picture of the
initial docking movement of the substrate across the cell membrane has still not emerged.
Although there is no X-ray structure of the DAT, mutational studies have shown that
multiple residues interact to form domains for DA and for various inhibitors including
cocaine. These residues are separated in the primary structure but may lie near each other
in the still unknown tertiary structures. 17 Since dopamine is positively charged at
physiological pH, negatively charged aromatic and polar amino acid residues on the DAT
are logical sites to be involved in substrate interaction. DA transport across the DAT has
three distinct phases: recognition, binding and transport. The DAT can only recognize
5
and bind cocaine but cannot transport it across the membrane. Conserved residue Αsp79
is involved both in DA transport and cocaine binding. 18 Tyr335, which is also a
conserved residue among monoamine transporters, appears to be important for DA
transport 1 s ' 19 Replacement of Phe 105 of ΤΜ2 by Ala showed decreased affinity for
cocaine, and replacement of Phe155 of ΡΜ3 by Ala showed decreased affinity for an
analog of cocaine compared to the wild-type transporter. Αsp313, Asp436 and Αsp376
are also involved in substrate recognition. 20
Regulation of DAT Protein kinase C (PKC) activation accelerates DAT endocytosis
via a clathrin- and dynamin-dependent mechanism. 21 PKC activation also increases
phosphorylation of the DAT. The major phosphorylation sites in the DAT are identified
as serine residues on the distal cytoplasmic N-terminus. Truncation of the N-terminal of
the DAT abolishes PKC-stimulated phosphorylation without impairing transporter
internalization. 22 In addition to PKC, other presynaptic proteins also regulate modulation
of transporter expression and activity. Endogenous DAT activity is regulated by
presynaptic dopamine subtype 2 (D2) receptors through enhanced DAT expression; this
modulation is lost in D2-receptor-deficient mice. 23 The oligomerization of the DAT as a
direr due to symmetrical crosslinking between cysteine residues located at the
extracellular face of ΤΜ6 has been observed. The mutations of ΤΜ2 leucine residues
eliminate both transporter delivery to the plasma membrane and interaction with wild-
type DAT. It has been proposed that ΤΜ2 may play an important role in transporter
assembly and the oligomerization process, which is essential for the trafficking of the
transporter to the cell surface.24'25
6
1.2 GBR 12909 as a Lead Ligand
GBR 12909 (1, Figure 1.2) was originally developed and tested in Europe as a potential
antidepressant as it was a potent and selective ligand for the DAT. 26 Its ability to produce
only a modest increase in extracellular DA and at the same time to attenuate cocaine's
ability to increase extracellular DA inspired interest to develop it as a therapeutic agent
for stimulant abuse. By blocking cocaine's binding to the DAT but allowing some
reuptake of DA, GBR 12909 could act as an antagonist or partial agonist. GBR 12909
differs from cocaine in several important ways: It has higher affinity but a slower
dissociation rate from the DAT than cocaine. It has a non-stimulating profile in normal
human volunteers as well as the ability to functionally antagonize cοcaine. 27-2θ
1.2.1 Molecular Modeling of GBR 12909 and its Analogs
Modeling the DAT selectivity of the GBR 12909 analogs is very challenging for three
reasons: (1) To date no X-ray crystal structure of the DAT is available, (2) The GBR
12909 analogs are conformationally very flexible, and (3) There are no rigid analogs of
GBR 12909. Therefore, a model must be developed using the information about the
biological activity of chemically-related structural analogs of GBR 12909. Since it is
well-known that a ligand does not necessarily bind to a protein in its global energy
minimum (GEM) conformatiοn, 30-34 it becomes imperative that the conformational space
of the ligand be thoroughly searched to locate minima that could serve as templates of the
ligand in three-dimensional quantitative structure-activity relationships (3D-QSAR)
studies. Locating minima becomes especially important in the case of flexible ligands
like GBR 12909 and its analogs, as these ligands have a minimum of eight rotatable
bonds. For flexible ligands, the number of minima attained can be very large. Accurate
location of minima depends on the algorithm used for searching conformational space as
well as on the quality of the molecular mechanics force field and charges used to
calculate the energy of the ligand.
The GBR 12909 analogs studied here are the piperazine analog, 2, and the
piperidine analog, 3 (Figure 1.2). Both analogs are somewhat less flexible than 1 and
therefore are easier to study computationally. They have fewer rotatable bonds than 1 on
the A- (or napthyl) side of the molecule, while the B- (or bisphenyl) side is exactly the
same as 1. The conformer populations of 2 and 3 generated in this work provided the
basis for a CoMFA study of the DAT/SERT selectivity of 50 GBR 12909 analogs carried
out by the Venanzi group. 35
Figure 1.2 Structures of GBR 12909, 1, and analogs 2 and 3 with marked torsion
angles under study and methylphenidate, 4.
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1.2.2 Conformational Analysis
Conformational analysis relates the change in the energy of a molecule to changes in its
bond angles, bond lengths, and torsional angles. As the flexibility (defined by the
number of rotatable bonds) of a molecule increases, the number of possible conformers
with relatively low energy increases dramatically. In fact complete and systematic
enumeration of all possible conformers (N) for specified number of rotatable bonds,
nbonds, at finite angle increments (δ) can be represented by Equation l.1. 36
As the number of rotatable bonds increases, for example as in the present study where the
number of rotatable bonds is eight, the problem of investigating all possible conformers
in a systematic fashion becomes computationally difficult. An alternative is the use of the
random search method proposed by Saunders.37 In this method, random sampling of the
conformational space provides a set of conformations for analysis. Though the sampling
is not exhaustive, the completeness of the set of conformations produced can be increased
by either increasing the number of iterations in a particular random search or by
conducting multiple random searches with a smaller number of iterations and using
different starting conformers of the molecule. In this way, the conformational space can
be searched to any degree of completeness. The probability of finding all possible
conformers during the random search is given by Equation 1.2, 37 where n is the number
of times each conformer was found.
Probability of finding all conformers = 1 - (0.5) 	 (1.2)
9
1.2.3 Molecular Mechanics Methods
The energy of a conformer obtained with a particular molecular mechanics force field
depends on the mathematical formula for the bond stretching, angle bending, torsional,
van der Waals and Columbic energy terms, as well as the associated empirical
parameters. Force fields are developed to represent structural data for a wide range of
compounds, yet they may have certain deficiencies. If one is unaware of these
deficiencies, it is possible to draw conclusions about the relationship between molecular
structure and biological activity that are based on artifacts in the force field rather than
physical reality. The Tripos38 and ΜΜFF9439-44 force fields are typically used for ligand
modeling and were used in the present study. Since flexible ligands can adopt a wide
range of closely-related conformations, it is possible that solvent could affect the relative
energy of the local energy minima calculated in the vacuum phase. In order to estimate
the solvent effect on ligand conformation and energy, the results of vacuum phase
calculations can be compared to results using continuum solvent models such as the ones
used in the present study: constant dielectric function and distance dependent dielectric
function. Force fields and solvent models are best compared by evaluating their effect on
a set of conformers of a ligand rather than by just comparing a single, low-energy
conformer. This conformer population approach, first suggested by Boyd and Coner, 45
has the advantage of allowing one to compare a full range of conformers found within a
certain energy window rather than just a single structure of each analog, and therefore
gives a better picture of the behavior of the different force fields.
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1.3 Objectives and Significance
The specific objective of the present work is
To study the effect of force fields and solvent models on selected
piperazine and piperidine GBR 12909 analogs in order to choose the
optimal force field and solvent model for conformational analysis of this
class of compounds.
The significance of this work is that it studies the treatment of the GBR 12909 analogs by
two different force fields. The analogs contain piperazine and piperidine moieties, which
are common to many pharmaceutically-important compounds. Since these analogs appear
to be important lead compounds in the search for a treatment for cocaine abuse, an in-
depth examination of the treatment of these molecules by different force fields and
solvent models is particularly relevant for accurate drug design. The results of this work
provided the basis for the Venanzi group's computational study of the DAT/SERT




All calculations were carried out on Silicon Graphics Origin 2000 workstations at New
Jersey Institute of Technology using either versions 6.9, 7.1 or 7.2 of the SYBYL
molecular modeling program (available from Tripos Inc., St. Louis, MO).
2.2. Analogs 2 and 3
Protonation of Analogs	 Studies of the pH dependence of dopamine binding to the
DAT46 indicate that dopamine most likely binds in the protonated state. In contrast,
similar studies of WIN 35,42847 a cocaine analog, indicate that the protonated and
neutral species have similar binding affinity. Our recent studies 48 on the conformational
potential energy surface (PES) of the dopamine reuptake inhibitor methylphenidate (4,
Figure 1.2) indicate that the local minima on the PES of the protonated species are fewer
in number but located in the same general region of conformational space as those of the
neutral species. It was found that conformers which correspond to the neutral and
protonated local energy minima could be grouped roughly into the same conformational
families. Therefore, calculations were carried out on the protonated forms of 2 and 3.
Since 2 is a piperazine, it is possible that either nitrogen could be protonated. Molecular
orbital theory calculations done by a group member, Dr. William Skawinski, determined
that the nitrogen proximal to the naphthalene moiety for 2 and 3 is the preferred site of
11
12
the protonation.49 This is the same nitrogen that Dutta, et α1. 50 showed to be required for
DAT binding.
2.3 Random Search
In the present study conformational analyses were carried out using the Random Search
(RS) option in SYBYL with the force fields, charge sets, and solvent models described
below. The RS algorithm is designed to locate the local minima on the conformational
PES. The algorithm randomly alters the values of chosen torsional angles and then
optimizes the geometry by minimizing the energy of the molecule at each new
conformation. The chosen torsional angles (Al, A2, Β1-Β6) are shown in Figure 1.2 for
analogs 2 and 3. The geometry of the starting conformer for each search was optimized
using the Powe11 51 minimization method with each respective force field and associated
charge set. One thousand search iterations were carried out. At each step in the iteration,
the eight torsional angles were randomly altered and the resulting structure was optimized
again using the Powell minimization method. The rings of 2 and 3 were held fixed as
aggregates with the side chains attached to the central ring in the equatorial position. A
convergence threshold of 0.05 and a non-bonded distance cutoff of 8.0 Α were used for
each random search. A conformer was accepted into the ensemble of conformers if it met
the following energy and root mean square (RMS) criteria: (1) Its RMS distance
difference compared to all other conformers was at least 0.20 A, and (2) Its energy was
within 20 kcal/mol of the energy of the conformer identified to have the lowest energy at
that particular step in the random search. The random search procedure ended after 1,000
steps. The energy cutoff was purposely set high in order to thoroughly probe the PES of
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the molecule. The relative energy of each conformer was calculated by subtracting the
absolute energy of the GEM conformer from that of each conformer. The parameters
used for the random search are summarized in Table 2.1.
2.4 Force Fields, Charges, Solvent Models
For both 2 and 3, four different RS runs were made using the following combinations: the
Tripos force field and Gasteiger-Ηϋckel atomic charges (in vacuum and solvent) with the
default distance-dependent dielectric function, and the MMFF94 force field and
associated MMFF94 atomic charges (in vacuum and solvent) with the default constant
dielectric function. The dielectric constant value was set equal to one for the vacuum
phase and 80 for the solvent calculations. The solvent calculations were performed by
William Roosma, supervised by Deepangi Pandit, as part of his master's thesis in
Computational Biology.























Gasteiger- Hϋckel or MMFF94
Distance Dependent - Tripos Default
Constant - MMFF94 Default
1.0 (Vacuum) or 80 (Water)
8.0 Α
On (Phenyl Rings, Naphthalene Ring,
Piperazine/Piperidine Ring)
15
2.5 Analysis of Conformer Populations
2.5.1 Molecular Shape
The distance of closest approach between the aromatic rings of the A- and B- sides was
used to give a gross indication of the extent to which the molecule assumes a "folded"
shape. The SYBYL molecular modeling program was used to identify the centroid of
each of the phenyl rings and ring 1 of the naphthalene ring (Figure 2.1a). For each
conformation the distance between the centroid of each phenyl ring (rings 3 and 4) and
that of ring 1 of naphthalene was calculated as D13 or D14, respectively. The lesser of
these two distances, LD, was defined as the distance of closest approach of the
napthalene and bisphenyl moieties. Virtual torsional (VT) angles were defined in order to
give an estimate of the degree to which the naphthalene and phenyl rings are offset (or
"swung away") from each other. The VT angle was defined by the following four points:
(1) the centroid of ring 1 of the naphthalene ring, (2) the nitrogen of the piperazine (or
piperidine) ring proximal to the naphthalene ring, (3) the nitrogen (for 2) or carbon (for 3)
to which the bisphenyl side chain is attached, and (4) the centroid of either phenyl ring.
These points are connected by the dotted lines on analog 2 in Figure 2.1b and indicate the
virtual torsional angles (VT 13 and VT 14) that define the relative orientation of the
napthalene and bisphenyl rings. Conformers were classified into shapes based on the
following LD/VT combinations, with LD given in Angstroms and VT13 or VT14 given in
degrees. Examples of typical shapes are given in Figure 2.2.
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The local energy minimum conformations identified by each RS run were assigned to
energy "bins" (in units of kcal/mol) on a histogram as follows: 0-4 bin: 0 < relative
energy < 4, 4-8 bin: 4 < relative energy < 8, and so on. Histogram energy profiles were
compared for the different RS runs.
Figure 2.1 Definitions of the closest distance and virtual angles. (a) Distance of
closest approach between the A- and B- sides is the lesser of the two distances D 13 and
D14. D13 is the distance between the centroids of rings 1 and 3; D14 is the distance
between the centroids of rings 1 and 4, (b) Points used to define virtual torsion angles:
VT 13 = l---N---N---ring 3 centroid and VT 14 = 1---N---N---ring 4 centroid.
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Figure 2.2 Typical conformers representative of each shape: blue - C, cyan - V.
magenta - U, yellow - S, Red - I. The yellow S shape overlaps the magenta U shape in
the upper right-hand portion of the figure.
2.5.3 Conformer Populations in Torsional Angle Space
Due to the impossibility of viewing the results in eight-dimensional torsional angle space,
the local energy minima from each RS run were plotted in two-dimensional torsional
angle space for all pairs of consecutive torsional angles: (Al, A2), (B1, Β2),... (Β4, Β5),
(Β4, B6), and (Β5, Β6). As will be seen below, the two force fields resulted in a
significant difference in the range of Β4 values taken on by the conformer populations of
2 and 3. Note that the torsional angle Β4 involves rotation around a C(sp 3 )-Ο(sp3 ) bond.
To examine this difference in detail, models of the B-side of the analogs were constructed




Two model compounds (5 and 6, Figure 2.3) were constructed to study the influence of
the bisphenyl moiety on C(sp3)-Ο(sp3) internal rotation. Note that 5 has the C(sp 3 )-
Ο(sp3) bond proximal to the bisphenyl group, as in 2 and 3, so that torsional angle 2 is a
model for B4; 6 has one less phenyl ring than 5.
2.6.1 Generation of Conformer Populations by Random Search Conformational
Analysis
Figure 2.3 Model compounds.
Vacuum phase RS conformational analysis was carried out for 5 and 6 using the protocol
described above and the search parameters in Table 2.1. All torsional angles were
allowed to vary for 5 and 6. The conformer populations were plotted in (torsional angle 2,
torsional angle 3) space.
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2.6.2 Calculation of Potential Energy Surface by Grid Search Conformational
Analysis
Since RS only locates the minima on the conformational PES, vacuum phase grid search
was also carried out on both 5 and 6 in order to obtain additional details about the PES
landscape. For each model compound, torsional angles 2 and 3 were altered in 10°
increments forming a grid of torsional angle points. At each grid point, the energy of the
molecule was minimized using the chosen force field , holding torsional angles 2 and 3
constant. Each PES grid was plotted using the Origin Pro 7 SR4, Version 7.0552 (Β552)
package (available from the OriginLab Corporation, Northhampton, ΜΑ). The grid
searches were conducted by Anuj Kumar, supervised by Deepangi Pandit, as part of his
master's project in Computational Biology.
2.6.3 Molecular Orbital Calculations
As will be seen in the Results section, for 5, the largest difference between the
conformational energy calculated by the two force fields was found in the region where
torsional angle 2 was between -60° and 60°. Not only were the barriers to internal rotation
significantly different, but also the conformational energy minima calculated by the two
force fields were found at very different values of torsional angle 2 in this range. The
same result was noted in the RS output for 2 and 3 for Β4: conformational energy minima
calculated by the two force fields were found at very different values of Β4 for Β4
between -60° and 60°.
To probe these differences, molecular orbital calculations were carried out on 5
using the GΑUSSIΑΝ03 program. 52 A "slice" was taken through the potential energy
surface of 5 by freezing torsional angle 3 at -30°. Then torsional angle 2 was incremented
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in 30° steps and the energy was minimized at each point using the HF/6-31G(d) and
B3LYP/6-31G(d) basis sets in vacuum phase. The C-O rotational barrier and the location
of the minima with respect to torsional angle 2 in the molecular orbital results were
compared to the molecular mechanics grid search results for rotation of torsional angle 2
with torsional angle 3 frozen at -30°. It should be noted that the molecular orbital
calculations here are not meant to provide a definitive calculation of C-O internal rotation
since MMFF94 was parameterized to a much higher level of theory.39
CHAPTER 3
RESULTS
3.1. Analogs 2 and 3
3.1.1 Conformer Populations from Random Search
The RS algorithm identified more than 700 distinct local energy minimum conformations
for 2 and 3 with the Tripos force field in both vacuum and solvent (vacuum: 728 for 2
and 718 for 3, solvent: 735 for 2 and 733 for 3). With MMFF94, the RS algorithm found
more than 600 distinct local energy minimum conformations in vacuum (643 for 2 and
632 for 3) and more than 750 in solvent (791 for 2 and 780 for 3).
a. Energy Profiles Figure 3.1 shows the number of conformers in each energy
bin for 2 and 3 for the Tripos and MMFF94 random search results. The percent
distribution of conformers among energy bins (i.e., the conformer energy profile) is very
similar for 2 and 3 in the MMFF94 force field, but somewhat different in the Tripos force
field. The MMFF94 vacuum phase conformer profile of 2 is similar to that of 3, as is the
MMFF94 solvent phase profile. However in the Tripos force field, 3 has a significantly
larger percentage of conformers in the 0-4 kcal/mol energy bin than 2 in both vacuum
and solvent phase. In all cases solvent significantly increases the percentage of
conformers in the 0-4 kcal/mol energy bin compared to the vacuum phase results.
b. Molecular Shape Tables 3.1-3.4 give the number of C, V, U, S and I shapes
of 2 and 3 in each of the energy bins, as well as the total number of conformers of each
shape and the total number in each energy bin. For the Tripos force field in vacuum and
solvent (Tables 3.1 and 3.2), 2 has more C shapes than 3 by an order of magnitude. The
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Figure 3.1 Energy distribution of conformers, Tripos and MMFF94 force fields in
vacuum and solvent. Relative energy in kcal/mol.
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Table 3.1 Energy Distribution of Molecular Shapes, Tripos Force Field, Vacuum Phase
a kcal/mol. Columns contain number of conformers in each energy bin.
b Total number of conformers of each shape. See text for definitions.
Table 3.2 Energy Distribution of Molecular Shapes, Tripos Force Field, Solvent Phase
a kcal/mol. Columns contain number of conformers in each energy bin.
b Total number of conformers of each shape. See text for definitions.
Table 3.3 Energy Distribution of Molecular Shapes, MMFF94 Force Field, Vacuum
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a kcal/mol. Columns contain number of conformers in each energy bin.
b Total number of conformers of each shape. See text for definitions.
Table 3.4 Energy Distribution of Molecular Shapes, MMFF94 Force Field, Solvent
Phase
a kcal/mol. Columns contain number of conformers in each energy bin.
b Total number of conformers of each shape. See text for definitions.
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number of C shapes in vacuum and solvent for the MMFF94 force field (Tables 3.3 and
3.4) is negligible for both analogs. The I shape predominates in all cases. Its percentage
varies from about 40-50% (Tripos) to 60% (MMFF94) of the total number of conformers
for both 2 and 3. The U shape is the second most favored shape with about 25-35% of the
total number of conformers for both force fields for both 2 and 3. Comparison of Tables
3.1 and 3.2 or Tables 3.3 and 3.4 shows that inclusion of implicit solvent has no effect on
the molecular shape profile (i.e. the distribution of conformers among molecular shapes).
c. Conformer Populations in Torsional Angle Space Plots of the
conformational energy minima in the torsional angle space of (Β2, Β3) and (Β3, Β4)
show no significant difference between the force fields and are given in the Appendix.
The (Al, Α2) plot is discussed below as an example of this case. Since B5 and Β6 are
correlated due to the constraints of the structure of the bisphenyl group, plots in (Β4, Β6)
and (Β5, B6) space give no additional information than plots in (Β4, B5) space, so the
first two are given in the Appendix.
(1) (Α1, Α2) Torsional Angle Space: Figure 3.2 plots the conformational energy
minima from the random search runs in (Al, Α2) torsional angle space. The minima are
color-coded by relative energy as described in the figure legend. The figure shows that
all the patterns are very similar, indicating that the local minima on the A-side of 2 and 3
are located in very similar regions of (Al, Α2) space for the Tripos and MMFF94 results
in vacuum and solvent. In all cases the conformational energy minima cluster into groups
(i.e. at Al = ±60°, ±180°) that have values of Al that differ by approximately 120°. From
the structure of 2 it can be seen that the three clusters correspond to the staggered
conformations which are the conformational energy minima for rotation around the
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Figure 3.2 Local minima of 2 and 3 in (A1, Α2) space. Torsion angles are given in degrees.
Minima are color coded by energy in units of kcaL/mol. GEM marked by circle. Plot symbols:
pink diamond: 0 - 4, green box: 4 - 8, blue triangle: 8 - 12, yellow box: 12 - 16, red box: 16 -
20.
27
Ν(sp3)-C(sp3) bond of the Al torsional angle. The pattern of minima along the Α2 axis is
more complex and corresponds to staggered conformations which are the conformational
energy minima for rotation around the C(sp 3)-C(sp2) bond of the Α2 torsional angle.
Similar behavior was seen in the conformational PES of methylphenidate, which also has
a piperazine ring separated from an aromatic ring by a methylene group. 48
Figure 3.2 also shows that the location of the global energy minimum (GEM)
conformer (indicated by a large circle) is influenced by both solvent and force field.
Except for the MMFF94 results for 3, for each analog in each force field, the GEM
conformer from the solvent study is located in a different region of (Al, Α2) space than
that from the vacuum phase study. Also, except for the Tripos and MMFF94 vacuum
phase results for 3, the GEM conformer from the Tripos results is located in a different
region of torsional angle space than that for the MMFF94 results.
(2) (B1, B2) Torsional Angle Space: Figure 3.3 shows the local minima of 2 and
3 in (B 1, B2) torsional angle space. All cases, except the Tripos vacuum and solvent
phase results for 2, show nine well-defined minima which result from combination of the
staggered conformations, which are the minima for rotation around the Ν(sp 3)-C(sp3)
bond (in 2) or the C(sp 3)-C(sp3) bond (in 3) in the B 1 torsional angle (at B 1 = +60°,
+180°), with those that are the minima for rotation around the C(sp3)-C(sp3) bond in B2
(at B2 = ±60°, ±180°). In contrast, the Tripos results for 2 give minima that take on a
range of B 1 values not seen in the Tripos results for 3 or in the MMFF94 results for 2 and
3. Since 2 and 3 differ only by a tertiary amine nitrogen versus a tetrahedral carbon in
the B 1 torsional angle, the difference in the conformer populations of 2 and 3 may be due
to differences in how the force fields treat a tertiary amine nitrogen atom type and,
ultimately, in the effect of that nitrogen on Ν(sp 3)-C(sp3) internal rotation.
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Figure 3.3 Local minima of 2 and 3 in (Β1, Β2) space. Legend same as Figure 3.1.
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This is illustrated in Figure 3.4. Using the conformer populations from the vacuum-phase
results for both force fields, for each conformer Figure 3.4 plots the distance of the
nitrogen atom in B 1 of 2 with respect to a plane formed by three neighboring carbon
atoms and compares it to a similar plot for the related carbon atom in 3. The figure shows
a distinctive difference in the pattern for the nitrogen of 2 in the Tripos versus MMFF94
force fields. In the Tripos case (Figure 3.4a), about 15% of the conformers have
somewhat a planar nitrogen (arbitrarily defined as a nitrogen with a distance with respect
to the plane between -0.30 and 0.30 A). For the MMFF results for 2 (Figure 3.4c),
essentially 100% of the conformers have a tetrahedral nitrogen. This seems to indicate
that during the RS procedure, the Tripos force field allows the nitrogen to attempt to
"flatten out", even though the B-side side chain was held fixed in the equatorial position.
In contrast, the MMFF94 force field keeps the nitrogen tetrahedral. Figures 3.4b and 3.4d
show that the related carbon atom in 3 remains tetrahedral during the RS with both force
fields. Similar trends are seen in the solvent-phase results (not shown).
(3) (Β4, Β5) Torsional Angle Space: Figure 3.5 shows the local minima of 2 and
3 in (Β4, Β5) torsional angle space. There are striking differences between the Tripos
and MMFF94 results. In the Tripos case, conformers cluster along the Β4 values of -60°
and 60°, with few conformers in the Β4 range between -60° to 60°. The MMFF94 results
present the opposite picture, with most conformers found for values of Β4 between -60°
and 60°. This difference between the two force fields with respect to Β4 is also
demonstrated in the plots of the local minima of 2 and 3 in (Β3, Β4) and (Β4, Β6) space
(see Appendix A).
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Figure 3.4 Number of conformers with distance of N or C relative to the plane of three
carbons identified on molecular structure. (a) 2, Tripos in vacuum phase, (b) 3, Tripos in
vacuum phase, (c) 2, MMFF94 in vacuum phase, (d) 3, MMFF94 in vacuum phase.
Conformers having distance greater than 0 and less than or equal to 0.1 are assigned to bin
labeled 0.1, and so on.
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Figure 3.5 Local minima of 2 and 3 in (Β4, Β5) space. Legend same as Figure 3.1.
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Note that the B4 torsional angle involves rotation around the C(sp 3)-O(sp3) bond.
Although the B3 torsional angle also involves rotation around the C(sp 3)-O(sp 3 ) bond, in
this case the two force fields agree that the minima for 2 and 3 are found for values of B3
close to -60° and 60°, rather than between -60° and 60° (see plots of minima in (B2, B3)
and (B3, B4) space in the Appendix). Since B4 is proximal to the bisphenyl moiety
whereas B3 is an additional bond length away, it is possible that the presence of the two
phenyl rings affects the minima for C(sp 3)-O(sp3) rotation differently in the Tripos and
MMFF94 force fields. In order to investigate these issues in more detail, molecular
mechanics and molecular orbital calculations were carried out on model compounds. The
results are described below.
3.2 Model Compounds
The model compound studies were designed to investigate the effect of the bisphenyl
moiety on internal rotation by comparing rotation around the C-O bond in 5 to that in 6.
Torsional angle 2 in 5 is the equivalent of B4 in 2 and 3. Figure 3.6 displays the results of
the molecular mechanics grid search calculation of the PES of 5 and 6. The low energy
conformers identified by the RS calculation are shown as white squares on the grid.
Comparison of Figures 3.6a and 3.6b shows a general similarity in the location of regions
of high and lοw energy for 5 in the two force fields. Both force fields find high energy
regions for torsional angle 2 between -180° and -120°, as well as between 90° and 180°.
Both force fields show regions of low energy for torsional angle 2 equal to ±60°.
However, the MMFF94 force field displays a broad region of low energy for 5 for
torsional angle 2 between -60° and +60°, while the Tripos force field shows a much
higher energy range in this region. Comparison of Figures 3.6a and 3.6c shows that
Figure 3.6 Vacuum phase potential energy surfaces of model compounds. Contours are
color-coded by relative energy (kcal/mol) as follows: Magenta (0-4); Green (4-8);  Β. 	(8-
12); Yellow (12-16); Red (16-20). (a) 5, Tripos, (b) 5, MMFF94, (c) 6, Tripos, (d) 6,
ΜΜFF94. Minima obtained from random search for corresponding model compounds are
shown as white squares.
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removing one phenyl ring from 5 to give 6 has little effect on the characteristics of the
Tripos PES. In contrast, comparison of Figures 3.6b and 3.6d shows that removal of one
phenyl ring leads to significant broadening of the low energy region on the MMFF94
PES. Therefore it seems that the bisphenyl moiety has a larger effect on internal rotation
of a proximal C-O bond in the MMFF94 force field than in the Tripos force field.
Molecular Orbital Calculations	 Figure 3.7 plots the results for C-O internal rotation
for 5 at the HF/6-31G(d) and B3LYP/6-31G(d) levels with torsional angle 3 set equal to -
30°. For comparison purposes, the "slice" through the PES of 5 for torsional angle 3
equal to -30° from Figures 3.6a and 3.6b is also shown on the graph. Figure 3.7 shows
that both the Hartree Fock (HF) HF/6-31G(d) and density functional theory (DFT)
B3LYP/6-31G(d) techniques give very similar results, with the global energy minimum
falling at -60°, local minima at -150° and 30°, a low rotational barrier (1.52 kcal/mol for
HF, 1.89 kcal/mol for DFT) at 0°, and a very high barrier at 120°. Overall, the molecular
mechanics results are qualitatively similar to the molecular orbital results. However,
there are some significant differences in the PES for torsional angle 2 between -60° and
60°. In contrast to the molecular orbital results, the MMFF94 force field locates the
minima at -30° and 30°, with a much small barrier (only 0.49 kcal/mol) at 0°. The Tripos
force field, however, gives a value at 0° (3.53 kcal/mol) which is significantly higher
than the molecular orbital and MMFF94 results, and locates the minima at -90° and 30°
with a barrier at -30° of 4.44 kcal/mol. This explains why so many of the MMFF94 RS
conformers of 2 and 3 are found in the region with B4 between -60° and 60° in Figure
3.5, whereas the Tripos results tend to cluster around B4 = +60° with no conformers
found at B4 = 0°.
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3.5, whereas the Tripos results tend to cluster around B4 = +60° with no conformers
found at B4 = 0 deg .
Figure 3.7 Rotational barrier of torsion angle 2 of 5 (vacuum phase) with torsion angle 3
fixed at -30°. Solid line with diamonds: HF/6-31G(d), solid line with circles: B3LΥΡ/6-
31 G(d), dashed line with squares: MMFF94 force field, broken line with triangles: Tripos
force field. Relative energy in kcal/mol.
CHAPTER 4
DISCUSSION
4.1 Effect of Implicit Solvent on Conformer Populations
In all cases, the inclusion of an implicit solvent model significantly increased the
percentage of conformers in the 0-4 kcal/mol energy range compared to the vacuum
phase results and affected the location of the GEM conformer in torsional angle space,
without changing the molecular shape profile of the conformer populations. It should be
noted that MMFF94 was parameterized for use in molecular dynamics simulations with
discrete water molecules 39 whereas MMFF94s was developed for use in energy
minimization studies.44 The two force fields give identical results for most systems and
differ only in their treatment of resonance-delocalized trigonal nitrogen atoms. 44 This
atom type is not found in the GBR 12909 analogs, making either force field a suitable
choice for the present study. Although the MMFF94 force field was not validated for use
with the implicit solvent model employed here, since this options is available in the
popular molecular modeling program SYBYL, it is of some interest to note its effect on
the conformer populations.
4.2 Effect of Force Field on Conformer Populations
To the best of our knowledge, the results of calculations with the Tripos force field and
Gasteiger-Hϋckel charge set have never before been directly compared to those obtained
with the MMFF94 force field for large, flexible molecules containing carbon, hydrogen,
nitrogen and oxygen atoms, such as the GBR 12909 analogs considered here. Since the
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Tripos force field was constructed and validated without atomic charges, 38 it is useful to
compare its behavior with the Gasteiger-Ηϋckel charge set, a frequent choice among
SYBYL users, to that of the more recent and more extensively-validated MMFF94 force
field,35, 39-44, 53
MMFF94 was parameterized for a wide variety of pharmaceutically-relevant
chemical systems using both high-level ab initio molecular orbital theory 39-42 and
experimental data. 43 The "core" parameterization involved, among other calculations,
geometry optimization of 500 molecular structures at the HF/6-31 G* level, 475 structures
at the ΜΡ2/6-31G* level, and 380 structures at a higher level including electron
correlation and triple zeta plus polarization basis sets. Conformational energies were
calculated in 250 cases at the "ΜΡ4SDQ/ΤΖΡ" level, i.e. triple zeta plus polarization
calculations at a defined approximation to the ΜΡ4SDQ level of theory. Approximately
1200 torsional profile structures, obtained by rotating a given torsional angle by a
specified increment, were calculated at the ΜΡ2/ΤΖΡ level derived from ΜΡ2/6-31 G*-
optimized geometries. The MMFF94 parameters were determined in a "mutually
consistent" fashion from all the available data using an iterative procedure in which each
type of parameter was optimized while using increasingly well-refined parameters for the
other parameter types. 39 This is different than "functional group" approach employed by
most force fields, including Tripos, in which certain parameters are fit to a portion of the
data, then frozen. MMFF94 also employs a unique functional form for describing the van
der Waals interactions.39
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In contrast, the Tripos force field (without charges) was validated against X-ray
structures by minimizing three cyclic hexapeptides, crambin, and 76 small organic
molecules. Thermodynamic barriers were calculated for 17 different conformational
energies, 12 stereoisomers, and 15 rotational barriers. 38
4.2.1 Parameterization of Tertiary Amine Nitrogen
Several differences were noticed in the conformer populations generated by the two force
fields. For example, MMFF94 gave very similar conformer energy profiles for 2 and 3,
in contrast to the results with the Tripos force field for which 3 had a significantly larger
proportion of conformers in the 0-4 kcal/mol energy bin than 2 (Figure 3.1). Although
for both force fields most conformers of 2 and 3 were found in the I shape, with the U
shape being the second most favored, only the Tripos force field allowed some
conformers of 2 to take on the C shape (Tables 3.1-3.4). Comparison of the plots of the
conformer populations in torsional angle space shows that both force fields yielded
similar plots for 2 and 3 in (Al, A2) space (Figure 3.2), and similar plots for 3 in (B1,
B2) space (Figure 3.3). But for 2, the (B1, B2) plots show that the conformers took on a
different range of values for B 1 in the Tripos versus the MMFF94 force fields. It should
be noted that for 2, although Al and B 1 both involve internal rotation around an N(sp 3)-
C(sp3) bond, the nitrogen in Al is protonated whereas the nitrogen in B 1 is not. For 3, B 1
involves internal rotation around the C(sp3)-C(sp3) bond.
In previous work, 54 we applied the singular value decomposition technique to all
eight torsional angles (A1,..., B6) of the Tripos vacuum phase conformer populations of
2 and 3. We uncovered differences in how the data separated along certain principal
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components and in which torsional angles were the chief contributors to those principal
components.54 This indicated an underlying difference in the conformer populations of 2
and 3 generated by the Tripos force field. Since 2 and 3 only differ by an unprotonated
tertiary amine nitrogen versus a tetrahedral carbon at the same location in the B 1
torsional angle, the difference in their conformer populations was attributed to the
treatment of the tertiary amine nitrogen by the Tripos force field.
In the present work, plots of the distance of the B! nitrogen of 2 and the
corresponding B1 carbon of 3 with respect to the plane of their neighboring carbons
(Figure 3.4) show that the Tripos force field allowed a significant percentage (15%) of
the conformers of 2 to have tertiary amine nitrogens to be somewhat planar, while both
Tripos and MMFF94 kept the B 1 carbon tetrahedral. It should be noted that various
conformers of 23 different amines were used in the "core" parameterization of MMFF94
and that the root mean square deviation (in degrees) for 96 out of plane angles in the set
of saturated amines was only 0.91 for MMFF94 compared to 57.5 for ΜΡ2/6-31 G*
method.39 Of the 76 small molecules tested with the Tripos force field, about half
contained various types of amine nitrogens, but statistics were given only for the rms
errors in bond lengths, bond angles, and torsional angles for the dataset as a whole. It
should be noted, however, that compared to MMFF94 the Tripos force field
overestimates the Ν(sp 3)—C(sp3) rotational barrier (in kcal/mol): methylamine (1.98-
experiment, 55 2.8-Tripos, 38 2.36-ΜΜFF9442), dimethylamine (3.62-experiment, 55 4.9-
Tripos,38 3 .52-ΜΜFF9442).
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The difference in how the force fields treat a tertiary amine nitrogen atom type
and, ultimately, the effect of that nitrogen on Ν(sp 3)-C(sp3) internal rotation appears to be
one source of difference in the conformer populations of 2 and 3.
4.2.2 Proximity of Bisphenyl Moiety to C-O Bond
The effect of the bisphenyl group on C(sp 3 )-O(sp 3 ) internal rotation appears to be another
source of difference between the force fields. The plot of the conformer populations of 2
and 3 in (B4, B5) space (Figure 3.5) showed striking differences between the Tripos and
MMFF94 force fields for behavior with respect to B4, whereas a similar plot in (B2, B3)
space (Appendix) showed little difference between the force fields. Torsional angles B3
and B4 both contain a C(sp3)-O(sp3) bond, but B4 is proximal to the bisphenyl group,
whereas B3 is one bond length further away (Figure 1.1). Calculations on model
compounds 5 and 6 showed that the MMFF94 force field is sensitive to the effect of the
bisphenyl moiety on C-O internal rotation (Figure 3.6). Although 25 types of aromatic
and heteroaromatic molecules along with various conformers of 14 types of conjugated
systems were used in the core parameterization of MMFF94, none contained the
bisphenyl moiety. However, MMFF94 has been shown to reproduce the C(sp 3)-C(sp2)
rotational barrier for ethylbenzene (1.16 kcal/mol, experiment; 1.19 kcal/mol, MMFF94;
1.10 kcal/mol, "MΡ4SDQ/ΡΖΡ").42 In the Tripos validation study,38 no bisphenyl group
was contained in the 76 small molecules studied and no C(sp 3)-C(sp2) rotational barrier
was contained in the 15 torsional barriers studied. It should be noted that the two force
fields use different torsional potential functions (Tripos — one term, MMFF94 — three
terms).
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4.2.3 C-O Internal Rotation
Calculations of C(sp 3 )-O(sp3) internal rotation in the model compound 5 (Figure 3.6)
showed that the MMFF94 force field allows a broad region of low energy between -60°
and 60°, with a very low barrier (0.49 kcal/mol) at 0°, in contrast to the high barrier (4.44
kcal/mol) at -30° noted with the Tripos force field. The HF/6-31G(d) and B3LΥΡ/6-
31 G(d) calculations were in qualitative agreement with the MMFF94 results. It has been
demonstrated that MMFF94, parameterized to the "ΜΡ4SDQ/ΤΖΡ" level in conjunction
with ΜΡ2/6-31 G*-optimized geometries, reproduces experimental conformational
energies more accurately than the HF/6-31 G* or ΜΡ2/6-31 G* methods. 42 Of particular
interest is the case of methylethyl ether, where the experimental value (in kcal/mol) for
the gauche-anti energy difference is 1.5, the "ΜΡ4SDQ/ΤΖΡ" result is 1.41, and the
MMFF94 result is 1.5. 42 MMFF94 also reproduces the experimental barrier for C-O
rotation in dimethyl ether, whereas Tripos significantly overestimates it (in kcal/mol):
2.7-experiment, 55 2.43-ΜΜFF94, 42 and 4.2-Tripos. 38 Various conformations of 14
different ethers were used in the core parameterization of ΜΜFF94. 39
The difference in how the Tripos and MMFF94 force fields treat C(sp 3)-O(sp3)
internal rotation is responsible for the fact that, in the random search calculations, the
local minima tend to collect at B4 values equal to ±60° for the Tripos force field, but at
B4 values between -60° to 60° for the MMFF94 force field.
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4.3 Summary
In summary, from comparison of the conformer populations of 2 and 3 generated by the
Tripos and MMFF94 force fields, it seems that there are subtle differences in how a
tertiary amine type nitrogen is handled by the force fields. The force fields also differ
significantly in their description of C-O internal rotation and the effect of the bisphenyl
moiety on C-O internal rotation. These subtle differences affect some characteristics of
the conformer populations collected during a random search. Ultimately, these
differences could affect the results of a 3D-QSAR analysis which depends on the
selection of certain representative conformers from a conformer population to act as
templates for the analysis. The present work suggests that it is important to check the
applicability of the force field for the types of questions one is attempting to answer by
computer modeling. In previous work, we used the Tripos vacuum phase conformer
populations of 2 and 3 to select representative conformers 56 as templates for 3D-QSAR
analysis of a series of 48 GBR 12909 analogs that differ by changes in the Aside only. 35
This seems an acceptable choice since the differences in the Tripos and MMFF94 force
fields were found to occur only for the nitrogen and oxygen on the B-side of the analogs.
4.4 Comparison of Conformer Populations of 2 and 3 to Methylphenidate
Methyiphenidate, 4, and the GBR 12909 analogs 2 and 3 share some pharmacophore
features that are typical of most dopamine reuptake inhibitors: an aromatic group in close
proximity to a basic nitrogen. Torsional angles Al and A2 control the relative orientation
of these important functional groups in 2, 3, and 4. In order to compare the behavior of
the A-sides of 2 and 3 to 4, the conformer populations of all three (from random search
calculations with the vacuum phase Tripos force field, Gasteiger-Ηϋckel charges, and
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distance dependent dielectric function with dielectric constant set equal to 1) were plotted
in (Al, A2) space. The conformer populations of 4 were taken from our previous work. 48
Figure 4.1 compares the location of all the local minima of 2 and 3 to those of
protonated 4 in (Al, A2) space and shows that methylphenidate is far more
conformationally restricted than 2 and 3. Although 4 has far fewer minima, they are
located in roughly the same region of (A1, A2) space as those of 2 and 3. This suggests
that 2, 3, and 4 may share a common pharmacophore for DAT binding that involves the
aromatic ring and nitrogen. However, the nitrogen in 4 is separated from the aromatic
ring by three bonds, while the nitrogen in 2 and 3 is separated from the aromatic ring by
only two bonds. For this reason, Figure 4.2 compares the distance of the nitrogen from
the centroid of the phenyl ring in 4 to the distance of the nitrogen in 2 and 3 from the
centroid of ring 1 of naphthalene. A distance range of 3.75-4.35 Α is common to all the
three analogs. For 2 and 3 all the conformers are in this range, while for 4, 43% of the
conformers are in this range. The fact that 2, 3, and 4 can orient their common
pharmacophore elements in the same way suggests that the Aside of the GBR 12909
analogs may attempt to bind to the DAT in a way similar to that of methylphenidate.
However, the long B-side of the GBR 129009 analogs may influence this interaction
through a range of additional interactions with the DAT protein. A more definitive
understanding of the DAT pharmacophore awaits the study of more rigid dopamine
reuptake inhibitors, such as the recent study of rigid analogs of methylphenidate.
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Figure 4.1 Tripos force field vacuum phase random search local minima of 2 (filled squares)
and 3 (filled diamonds) compared to local minima of 4 (open triangles) in (Al, A2) space.
Torsion angles are given in degrees.
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Figure 4.2 Number of conformers with given distance of N from centroid of the aromatic
ring. Tripos in vacuum. Conformers having distance greater than 3.55 and less than or
equal to 3.60 were assigned to bin labelled as 3.55, and so on. (a) 2, (b) 3, (c) 4.
PART II
3D-QSAR STUDIES OF SALVINORIN A




Opioid receptοrs (OR, Figure 1.1) are members of the seven transmembrane-spanning.
G-protein coupled receptor (GPCR) superfamily and the subfamily of the rhodopsin
receptor. The genes for four opioid receptors (the mu (μ) opioid receptor (MOR), the
kappa (κ) opioid receptor (KOR), the delta (δ) opioid receptor (DOR), and the
nociceptiii/orphanin FQ receptor (NOP-R) also known as ORL-1) have been cloned.2,3  In
general, μ, κ, and δ opioid receptors are about 60% identical to one another in terms of
amino acid composition. The transmembrane domains and intracellular loops have the
greatest similarity (73-76% and 86-100%, respectively), while the N terminus,
extracellular loops and C terminus regions are the most structurally divergent.
Figure 1.1 Schematic representation of the opioid receptor. 3
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Opioid receptors can regulate the range of effectors, which are small molecules
that, when bound to an allosteric site of a macromolecule, cause either a decrease or an
increase in the activity of the macromolecule. They can regulate macromolecules such as
adenylate cyclase, Ca+2 channels, phospholipase C, Κ+2 channels and mitogen-activated
protein kinases. 1 By virtue of these effectors, ORs are capable of participating in the
process of signal transduction in which a signal from outside the cell (for example, from
the binding of OR ligands) can control function within the cell (for example, through an
interplay between the OR and effectors). ORs are activated both by endogenous peptides,
including dynorphins, enkephalins and endorphins, as well as exogenous opioid drugs
such as morphine and heroin. 3 Dynorphins and enkephalins are considered to be of major
importance to the central nervous system (CNS) because they are the neurotransmitters
involved in pain perception, cognitive function and endocrine functions. Beta (β)-
endorphin is not considered to be as important because it is expressed in low levels and is
only associated with the neuronal pathway originating from hypothalamic nuclei.
Dynorphin A interacts preferentially with the KOR while enkephalin and β-endorρhin
mainly interact with the MOR and DOR. According to the "address-message" 4 '5 concept,
the "message" component of the ligand or peptide specifies general OR recognition and
the "address" portion confers selectivity by specific recognition at a particular OR.
Furthermore, the "message" part is connected to signal transduction, while the "address"
part provides additional binding affinity and is not necessary for signal transduction.
Ligands for all three opioid receptors (MOR, DOR and KOR) have some
analgesic effect,6 however all lead to unpleasant side effects such as addiction, sedation,
decreased respiratory function, seizure and gastrointestinal complications. It has been
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recently noted that KOR agonists of the peripheral nervous system (that is, the nerves and
neurons that reside outside the CNS to serve the limbs and organs) would have few side-
effects and limited abuse potential. Recently, salvinorin A was identified as a highly-
selective (higher binding affinity for the KOR than the MOR or DOR) and efficacious
KOR agonist. $ Salvinorin A can impair perception and coordination but at present limited
information is available on such issues and more data is required to understand its effects
on humans. 9 Recently, in a comprehensive review, 10 it was noted that KORs appear to be
implicated in the modulation of the abuse-related effects of CNS stimulants and may
antagonize cocaine's abuse-related effects. For example, KORs appear to modulate DA
levels 11 and affect cocaine-induced locomotor activity in rats. 12 KOR agonists may,
therefore, present a new direction in the search for a treatment for cocaine abuse.
Although these compounds are effective in reducing cocaine self-administration in
monkeys, they produce unpleasant side effects. 13 The inclusion of MOR
agonist/antagonist activity in the design of novel KOR agonists has been suggested as
way to minimize these side effects 14 and possibly lead to new agents for the treatment of
cocaine abuse. Thus it is possible that a study of salvinorin A and its analogs may help to
illuminate the role of the KOR system in addiction and analgesia in humans.
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1.2 Salvinorin A
Salvinorin A has been recently identified as a naturally-occurring hallucinogen, (1,
Figure 1.2) from the plant Salvia divinorum which activates the KOR selectively and
potently.8' 15 Salvinorin A is unique as it is the only known natural non-nitrogenous agent
that binds to the human ΚΟR. 8 It does not show structural similarity to other known
nonpeptidic opioid receptor ligands (such as 2-6, Figure 1.2) and due to the absence of
nitrogen, it also shows qualitatively different binding than other traditional KOR ligands.
It does not show any significant activity at the MOR, DOR, ORL-1, or other tested
GPCRs, neurotransmitters or ion channels. Due to the role of KORs as a target of
psychomimetic agents and because salvinorin A is a selective agent, it may represent a
novel lead compound for psychotherapy with possible potential in the treatment of
schizophrenia, dementia, and bipolar disease. In the only reported behavioral study of
salvinorin A in nonhuman primates, 16 salvinorin A also showed potential to reduce
cocaine self-administration. It can also serve as a novel template for the development of
non-addictive analgesic opioids.17' 18 Since salvinorin A has only recently been discovered
as a KOR agent, limited data on biological effects are available. But initial results seem
to indicate that salvinorin A may have potential usefulness in the area of analgesic and
addiction research.
1.2.1 Structure-Activity Relationships of Salvinorin A Analogs
The exact nature of the molecular interactions between salvinorin A and the KOR is not
known as no crystal structure of the KOR is available. Recent experimental structure-








Figure 1.2 Structures of opioid ligands: 25 salvinorin A (1) (showing the importance of
various moieties to KOR binding affinity), morphine (2), cyclazocine (3), fentanyl (4),
SNC 80 (5), U50,488Η (6), and 3FLΒ (7).
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and the furan ring are required for activity but that the lactone and ketone functionalities
do not play a role in binding (See 1 in Figure 1.2). 1920 The nature of the 2-position 21
substituents of salvinorin A also plays a critical role in binding affinity (Κ I) at the
ΚΟR15'21-24 and ΜΟR. 25 '26 However, the primary focus of the present modeling study is
to understand the effect of the 2-position substituents of salvinorin A on the KOR binding
affinity. Prisinzano, Rothman, and coworkers2°'  23 ' 24 ' 26'27 have studied a series of about 55
salvinorin A analogs, of which 33 were used in the present three-dimensional quantitative
structure-activity relationships (3D-QSAR) modeling study (Table 1.1). A C-8 hydrogen
was found to be favored at the β-position as opposed to the α-position. The major KOR
SAR used for this study is summarized here. Comparison of 1-6 in Table 1.1 shows the
effect of the 2-position side chain length on the KOR binding affinity. Increasing the
length by one or two carbons compared to 1, as seen in 2 and 4, had little effect on the
KOR affinity, while additional chain length (5 and 6) decreased KOR affinity. The effect
on KOR affinity was further explored by the addition of an aromatic ring at position 2 as
in 8-16 and 21-30. Increasing the number of methylene spacer units between the carbonyl
and phenyl groups (as in 13 and 14) resulted in decreased affinity at the KOR compared
to 8.
Eight analogs (9-11 and 21-25) explored the effect of ring substitution at the 2-
position. The effect of halogen substitution on the phenyl ring can be seen by comparing
the affinity of 9, 10, and 11 (bromine substitution) or 24 and 25 (fluorine substitution) to
that of 8. Substitution of bromine at positions 2 or 3 (9 and 10, respectively) had little
effect on KOR affinity. In contrast, substitution at the 4-position of the benzene ring (11)
had the greatest effect in terms of decreasing the KOR affinity. Fluorine substitution at
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the 2 and 3 positions (24 and 25, respectively) paralleled the affinity changes noted with
bromine, except that KOR affinity was decreased to a greater extent. The effect of
methoxy substitution on the phenyl ring (21-23) was to decrease KOR affinity.
The effect of the size and nature of the aromatic substituent at the 2-position of
salvinorin A was explored in analogs 26-30. The extended aromatic system, 1-
naphthalene (26) has reasonable binding affinity at the KOR compared to 2-naphthalene
(27) which has significantly poorer KOR affinity. However, use of a sulfur in the
aromatic system, i.e. 2-thiophene and 3-thiophene (15 and 29 respectively), led to KOR
binding affinities on par with 8 for 29 but a slight drop was observed for 15. Use of an
oxygen in the aromatic system (28) resulted in almost the same KOR affinity as 8, but
use of a nitrogen in the aromatic system (12) significantly decreased KOR affinity.
Analogs 32 and 33 show the importance of the methoxy moiety because in its absence,
binding affinity drops.
Several analogs studied by the Prisinzano and Rothman groups were not included
in the present modeling study and are not shown in Table 1.1. Analogs with 2-position
sulfonate substituents were not included because it has been pointed out that they might
be binding in a different manner at the KOR. 25 Analogs with changes in the furan ring
were excluded because the focus of the present study is on the 2-position substituents.
This position has the most SAR data associated with it and the KOR binding affinity
appears to be very sensitive to changes at this location. The 2-position trimethyl silicate
analog was not included because molecular mechanics parameters for silicon are not
available.
54
In summary, the SAR data in Table 1.1 contain a wealth of information relating
KOR affinity to changes in the molecular structure and properties at the 2-position of
salvinorin A. Certain substituents provide only a change in the shape (or bulkiness) of
the molecule. Others, due to their electron-donating or electron-withdrawing properties,
affect the electronic properties of the molecules as whole. Some substituents provide
various combinations of steric and electrostatic effects. However, the large amount of
information in Table 1.1 is difficult to visualize as a whole. For that reason, use of the
3D-QSAR techniques described in Chapter 2, in combination with further synthetic and
pharmacological studies from the Prisinzano and Rothman laboratories, may prove to be
useful in the design of novel KOR agents.
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Table 1.1 Binding Affinities of Salvinorin A Analogs at the Kappa Opioid Receptor
(KOR) Using [125 I] IΟΧΥ as Radioligand. Reference listed in the superscripts. Test set
marked by asterisk.
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1.2.2 Molecular Modeling of the Salvinorin A-KOR Complex
Το date ; four different models (Figure 13) have been proposed for the binding
orientation of salvinorin A in the KOR site. The models incorporated, where available,
information from mutational and/or chimeric studies of the KOR. Each binding model
was based on a different molecular model of the KOR. Each of the KOR models was
derived using a different modeling protocol. No X-ray crystal structure of the KOR
exists. The opioid receptors are GPCRs and the only X-ray structures of GPCRs available
are those of bovine rhodopsin. As will be seen below, subtle differences in the underlying
KOR molecular models significantly impacted the postulated binding models of
salvinorin A.
Figure 1.3 Molecular models of the salvinorin A-KOR Binding. Groups postulated to
be important for the activity in colored boxes.8, 28, 29 , 31
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Roth and coworkers $ initially proposed a model (Roth Initial Model, Figure 1.3a)
based on a structure of the KOR,28 derived without any experimental structural data for
bovine rhodopsin, by means of a distance geometry algorithm using hydrogen bonding
constraints. 28 Subsequently this KOR model was revised29 (Roth Revised Model, Figure
1.3b) by homology and molecular modeling based on a 2000 X-ray structure of
rhodopsin. 30 The initial model of Ferguson and co-workers31 (Ferguson Initial Model,
Figure 1.3c) was derived using their 1996 homology model of the KOR. 32 Their revised
mode133 (Ferguson Revised Model, Figure 1.3d) was derived by homology and molecular
modeling of the KOR based on a 2004 X-ray structure of rhodopsin with a bound
antagonist. 34 Energy minimization and molecular dynamics simulation of salvinorin A in
the binding site were carried out to obtain a KOR-agonist bound conformation. 33
Figure 1.3 shows that the four models differ in several significant aspects.
Colored boxes surround those chemical moieties postulated by all four models to be
important to salvinorin A-KOR binding: the 2-position substituent (red box), the 4-
position substituent (blue box), and the furan ring (black box). The initial Roth model
postulated the involvement of the lactone carbonyl group (green circle) in molecular
interactions with the KOR (hydrogen bonding to Tyr139), a hydrogen bonding interaction
between the 2-position carbonyl oxygen and the hydroxyl hydrogen of Tyr313, a
hydrogen bonding interaction between the furan ring and the amino group of Gln 115, and
a hydrogen bonding interaction between the 4-position carbonyl oxygen and the hydroxyl
hydrogen of Tyr312. Since mutation of Tyr139 to Ala had essentially no effect on
salvinorin A binding affinity and mutation to Phe had only modest effects, 29 the revised
Roth model (Figures 1.3b) no longer postulated a hydrogen-bonding interaction between
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the lactone carbonyl and Tyr139 of the KOR. In addition, mutating the Τyr313 residue to
Phe resulted in no loss of binding affinity, 29 while mutating it to Ala gave a dramatic
decrease in affinity. This indicated that a hydrophobic interaction between the 2-position
methyl group and the aromatic ring of Tyr is more likely, as shown in the revised model
(Figure 1.3b). Also mutating Try 119 or Try320 to Phe or Ala resulted in significantly
decreased affinity, and mutation of Tyr312 to Phe or Ala had little affect on binding
affinity29 so the revised Roth model postulated the stabilization of the furan ring by
hydrogen bonding interactions with the hydroxyl hydrogens of Tyr119 and Tyr 320 and
postulated stabilization of the 4-position substituent by hydrophobic interactions with the
lipophilic portions of G1u297 and I1e294.
The initial Ferguson model 3 ί was developed to explain the results of chimeric
opioid receptor and single point mutational studies. 31 As above, mutation of Gln 115 to
Ala resulted in significant decrease in affinity, but the initial Ferguson model (Figure
1.3c) postulated a hydrogen bonding interaction between the amino group of Gin 115 and
the lactone carbonyl oxygen of salvinorin A. This is in contrast to the initial Roth model
which postulated hydrogen bonding between the furan oxygen and Gin! 15, as well as the
revised Roth model which eliminated the lactone oxygen as a significant participant in
the binding interaction. The revised Roth model postulated the stabilization of the furan
ring of salvinorin A by both Try119 and Tyr320. However, in the KOR model used for
the initial Ferguson model, these residues are 15 Α apart. As a result, the initial Ferguson
model postulated a π-stacking interaction between the furan ring of salvinorin A and the
aromatic ring of Τyr320 at one end of the binding site, and a hydrophobic interaction
between the methyl group of the 4-position of salvinorin A and the aromatic ring of
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Tyrl 19 at the other (see Figure 1.3c). This latter interaction is similar to that postulated to
be between the 2-position methyl and Tyr313 in the revised Roth model. In the initial
Ferguson model, the 2-position side chain was stabilized by both Tyr312 and Tyr313,
whereas in the revised Ferguson model (Figure 1.3d), the ester oxygen of the 2-position
side chain was postulated to interact with the amino group of Gln 115 and the 4-position
side chain was stabilized by interaction with Tyr313. The initial and revised Ferguson
models agree in involving the furan ring in a π-stacking interaction with Tyr320, but
differ in the other major points of the interaction.
In summary, it is clear that differences in the underlying KOR molecular model
can lead to significantly different postulated binding models. The difficulty in
constructing an accurate salvinorin A-KOR binding model lies not only in determining an
accurate protein structure but also in deciding on the most appropriate orientation of the
ligand in the binding site. The modeling of salvinorin A binding to the κΟR is not
straightforward for two reasons. First, salvinorin A lacks the nitrogen which is used by
modelers to anchor the other KOR ligands in the binding site since it is believed that
cationic amino charge on the opioid ligand interacts with the side chain carboxyl group of
an aspartate residue (Αsp138) located in TM III of the opioid receptor. 25 In the absence of
a nitrogen, it is not obvious how salvinorin A orients itself in the site. Second, the
homology between the κΟR and rhodopsin is only in the range of 25-29% which is much
less than the 50% homology recommended to obtain a reasonable model using homology
modeling techniques. 35 Although the four models were developed in conjunction with the
available data from mutational, chimeric, and SAR studies, it appears that there may still
be some uncertainty as to the optimal salvinorin A-KOR binding mode. The residues
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responsible for binding and the types of interactions involved in the binding differ
considerably from one model to another. Clearly, the determination of the precise
location of salvinorin A in the KOR binding site is a challenge yet to be met. For this
reason, ligand-based modeling techniques, such as the 3D-QSAR methods described
below, provide a complementary approach to the protein modeling studies. Since the
ligand-based techniques are independent of the protein structure, they do not suffer from
the drawbacks associated with protein homology modeling and the uncertainty in the
appropriate ligand orientation in the binding site.
1.3 Ligand-Based 3D-QSAR Modeling
There is no X-ray structure of the KOR and homology modeling of the protein would
constitute material for a thesis in itself. As discussed above, four conflicting models of
salvinorin A-KOR binding interaction based on homology models of the KOR have been
proposed. Also, the SAR of the analogs in Table 1.1 does not clearly indicate whether
hydrophobic or hydrogen bonding interactions contribute to the formation of the ligand-
KOR complex. In this scenario, 3D-QSAR studies may shed some light on the types of
interactions with the receptor that are favored at certain locations in the ligand, thereby
complementing the techniques used to develop the binding models.
Comparative Molecular Field Analysis (CoΜFΑ) 36 '37 is a 3D-QSΑR method
which relates the shape-dependent steric and electrostatic fields of molecules to their
biological activity (here their KOR binding affinity). This technique describes 3D
structure-activity relationships in a quantitative manner. CoMFA models in the present
work were developed in an attempt to elucidate the molecular properties of the 2-position
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salvinorin A analogs responsible for their binding to the KOR. As will be seen in the
Results section, CoMFA models identify the location of those steric and electrostatic
fields around the analogs that contribute significantly to the binding affinity. This will
provide some understanding of the "hot spots" in the molecular substructure which are
most involved in the binding and may provide some insight into what chemical changes
could lead to optimal interaction between the ligand and the receptor.
CoMFA has been extensively used since its introduction in 1988. It is evident
from the fact that the original CoMFA paper 36 has more than a thousand citations, and
this does not take into acccount the unpublished CoMFA studies done in drug companies.
CoMFA studies have been conducted on ligands for the MOR and DOR as well as other
KOR ligands,38-43 but the present work is the first CoMFA study on salvinorin A analogs.
There has been only one ligand-based modeling study of the KOR binding affinity of
salvinorin A analogs, 33 but the CoMFA methodology was not used in that study. The
weakness of that study lies in the fact that it used SAR data compiled from several
different laboratories. This is problematic since the same analogs, when tested in different
laboratories, can show a different rank order of binding affinity due to the subtle
differences in the pharmacological protocol. The theory and principles behind CoMFA
are discussed in the next chapter.
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Objective and Significance
The objective of this work is to model the KOR binding affinity of 2-postion salvinorin A
analogs in order to propose new analogs with improved binding affinity. The modeling
will be carried out using the 3D-QSAR method of CoMFA to identify regions of
salvinorin A where changes in steric bulk or electrostatic properties, for example, may to
lead to analogs with improved binding affinity for the KOR. Our results will be shared
with the Prisinzano and Rothman groups to assist in the identification of novel salvinorin
A analogs which will be synthesized and tested for their KOR binding affinity with the





The first step in the series of biochemical events which leads to the observed biological
activity of a drug is its interaction with the target macromolecule. This interaction is
influenced by the degree of steric and electrostatic complementarily between the surface
of the drug (or ligand) and that of its protein binding site. The biological activity is some
experimentally measurable property of the drug-receptor complex, such as the binding
affinity of the drug for the protein. Α 3D-QSAR study is the analysis of the quantitative
relationship between the biological activity of a set of compounds and their molecular
properties (based on steric, electrostatic, hydrophobic and other molecular "fields")
calculated in 3D space using statistical methods. In the absence of structural data about
the receptor, as in the present study, this type of analysis may help to identify the
molecular features of a ligand responsible for its binding affinity and to predict the
biological activity of ligands not yet tested The underlying assumptions of 3D-QSAR
methods discussed by Oprea and Waller44 are: 1) The compounds in the modeling study
cause the observed biological effect; 2) Only a single conformation of the drug is
involved in binding; 3) All modeled compounds bind at the same site; 4) The measured
biological activity can be explained mainly as the result of enthalpic processes;
5) Entropic terms are similar for all modeled compounds; 6) The system is considered to
be at equilibrium and kinetic parameters are not considered; i.e., the on and off rates are
similar for all the compounds; and 7) Solvent effects, diffusion and transport are not
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necessary to explain the observed biological activity and so are not included in the
modeling calculations.
There is considerable evidence that ligands do not bind to proteins in their lowest
energy (or global energy minimum) conformation.45-49 Flexible ligands may take on a
large range of conformations that are very similar in energy. Rigid ligands, in contrast,
have only a small number of conformers available at low energy. As a result, rigid
compounds give important clues as to the bioactive (or binding) conformation of the
drug. If a rigid analog with only one possible low-energy conformation is shown to have
high binding affinity for the receptor protein, then it is a reasonable assumption that its
conformation is the bioactive conformation. A 3D-QSAR analysis requires that a
particular ligand conformation be selected as a template for superposition (or alignment)
of the other compounds in the study. The results of the analysis are very sensitive to the
conformer chosen as the template. In the optimal situation, the set of compounds under
study would contain a one-conformer rigid analog with high binding affinity. This
compound would be used as the template, the other molecules in the series would be
aligned to this structure, and the 3D-QSAR analysis would be carried out, potentially
resulting in a predictive model relating molecular structure and properties to biological
activity. However, many series of compounds of interest may not have such an obvious
choice for the template, and a more flexible molecule must be chosen. In a study
investigating how to best align molecules for 3D-QSAR, Klebe and Abraham 50 pointed
out that it is not necessary for structurally similar compounds to superimpose exactly in
the same binding site. The alignment used for superposition of the ligands, therefore,
should not be assumed to be the conformation in which ligand binds to the
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macromolecule. An effective molecular alignment should superimpose molecules to
describe the cause of their different biological activities but not the consequence, i.e., it
should reflect rather than reproduce reality.s 1
2.2 Comparative Molecular Field Analysis (CoMFA)
CoMFAs2 '53 is a 3D-QSAR method which is performed on a series of molecules to
compare differences in their molecular potential energy fields (by default steric and
electrostatic fields, although other fields can be considered) and to correlate them to
changes in biological activity. 44 The Lennard-Jones 6-12 function is used to calculate the
steric potential and a simple Coulombic function is used for the electrostatic potential to
describe the molecular interaction between each molecule in the series and a probe atom.
Figure 2.1 The CoMFA Process.
Source:Reprinted from SYBYL QSAR Manual, Tripos, Inc.
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The CoMFA process is depicted in Figure 2.1. Each molecule in the series is aligned (or
superimposed) according to a designated rule and then enclosed by a 3D lattice of
regularly-spaced points. The boundary of the lattice walls extend at least 4 Α beyond the
union volume of aligned or superimposed structures. The distance between neighboring
grid points is typically 1-2 Á. Each row of the table in Figure 2.1 describes the fields
exerted by a particular compound (Cpdl, Cpd2, ...) in the series, in a particular
conformation, on any surrounding atoms.5 1,53 In other words, each row corresponds to a
compound in the study and the collection of columns for each row corresponds to its
fields. For a particular ligand in the series, e.g. Cpd l , at the first grid point the total steric
(S001) and electrostatic (E001) intermolecular interaction energies of each of the atoms
in the ligand with each of the atoms in the probe molecule are calculated. The probe
molecule is then moved to the second grid point and the calculations repeated to yield
S002 and E002. This process is repeated for all the grid points. The same process is
performed for all the other compounds in the series (Cpd2, Cpd3,...). The data table in
Figure 2.1 contains the information used as input to the CoMFA calculation. It contains
the experimental biological activity data ("Bio", the dependent variable) and the
intermolecular interaction energies, or fields ("S001",.. ."E001",..., the independent
variables). The objective of the CoMFA technique, as of any 3D-QSAR method, is to
find an equation that relates the biological activity of a series of compounds to their
molecular properties, such as steric and electrostatic fields.53
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2.3 Principal Component Analysis (PCA) and Partial Least-Squares 44 ' s 1 , 54
Typically, there are relatively few (20-100) molecules in the series, but thousands of
molecular property values for each molecule. It is difficult or almost impossible to solve
a series of such equations. Multiple linear regression (MLR) does not work as there are
more molecular property values than compounds, and the properties are correlated. In
this situation, principal component analysis (PCA) is useful. PCA constructs the
directions or principal components ordered in terms of the amount of variance in a
dataset. For example if the dataset is CoMFA field values (X matrix), the principal
components capture the variation in the CoMFA fields. These components can be used to
explain the biological activity (Υ matrix). However, there is no guarantee that the
principal components derived by PCA using CoMFA fields are relevant for biological
activity. Partial least squares (PLS), or projection to latent squares, finds components
from X that are also relevant for Υ. This is achieved by searching for a set of
components (PLS components or latent variables) which can explain the covariance
between X and Υ. In other words, latent variables relevant to the biological activity are
constructed by the PLS algorithm. The following constraints are simultaneously satisfied
by the PLS algorithm: 1) the latent variables are orthogonal, 2) error is minimized, and




The internal predictive ability of a 3D-QSAR model is assessed by the technique of
cross-validation. In this technique one or more compounds are excluded from the input
data set and a PLS model is derived from the remaining compounds. Then the activity for
the omitted compounds is predicted and the resulting individual squared errors of
prediction are accumulated. Sample-distance Partial Least Squares (SAMPLS) 67 vastly
speeds up crossvalidation calculations for PLS analyses involving CoMFA fields.
Figure 2.2 The crossvalidation process.
Source: Reprinted from SYBYL QSAR Manual, Tripos, Inc.
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The important statistical parameters obtained from the cross-validation are the Predictive
Residual Sum of Squares, (PRESS), the "cross-validated r-squared", q 2 or Q2 , and the




Here, Ypred = predicted value of the biological activity, Yobs = observed value of the
biological activity, Ymean = the best estimate of the mean of all values that might be
predicted, n = number of rows and c = number of PLS components.
Generally, q2 increases as the first few PLS components (or latent variables) are
added to the model, then reaches a plateau or drops upon addition of more PLS
components variables. This means that additional PLS components describe properties
that are not related to the biological activity. These irrelevant PLS components should not
be included in the model as they can have a detrimental effect on the predictivity of the
model. The value of q2 is generally between 0.0 (corresponding to no model) and 1.0
(corresponding to a perfect prediction). There is a possibility of getting a negative q 2
when one or more unique compounds are present in the dataset and cross-validation relies
on the properties of a single compound. In this study the lowest number of latent
variables (or components) with a reasonably high q2 and the lowest standard of error of
estimate was selected as the optimal number of PLS cοmponents. 55 The optimal number
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of components was used to construct a non-cross-validated (NCV) model, or "full PLS"
model, in which all the compounds of the dataset are used to develop the model. This full
model gives the conventional r2 (or R2), calculated as shown in Equation 2.9, which
measures how well a particular model fits the data.
(2.9)
Here, SS(F) is the sum of the squares of the y residuals and SS(Υ) is sum of the squares
of the y variables. The NCV model can be used to further improve q 2 by performing PLS
Region Focusing,56 ' 57 an iterative procedure which refines a model by increasing the
weight for those lattice points which are most relevant to the model.
2.3.2 Types of Validation
Though cross-validation is an internal validation method, the very nature of the cross-
validation method overestimates the predictive power of the model based on datasets with
redundancy in properties and underestimates the predictive power of the model in which
each compound is unique in its set of properties. 51 '58 '59 The drawbacks of the cross-
validation technique can be overcome in part by dividing the whole dataset into a
"training" set and a "test" set and applying additional techniques to better assess the
predictivity of the model and evaluate the stability and robustness of the model. The
compounds of the training set are used to construct 3D-QSAR models which are then
used to predict the activities of compounds in the test set. In addition, the technique of
progressive scrambling (PS), 60 also known as y-scrambling, can be applied to the training
set to address redundancy in the dataset, i.e. molecules which have similar CoMFA field
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values. Compounds of the test set (compounds not used in developing the model) are
used as a tool for external validation of the mode1. 59 ' 61 The predictivity of the model is
tested by seeing how well it predicts the known biological activity of these compounds.
a. Internal Validation: As the first step in PS, rows are sorted based on the biological
activity. Then they are partitioned into a number of bins specified by the user. Within
each bin, the dependent variables (biological activities) are scrambled or reshuffled a
certain number of times specified by the user. Each such scrambling is characterized in
terms of the correlation of the scrambled responses with the unperturbed data
SAMPLS67 is applied to the perturbed data set to obtain the cross-validated correlation
coefficient (q2) and standard error of prediction (SDEP) both as a function of
process is repeated by decreasing the number of bins by 1 for each iteration until a user-
defined minimum number of bins or 2 comes first. The value of cSDEP is obtained by
calculating SDEP at a user-defined critical point, typically 0.85. The Q 2 (Equation 2.10)
are the important statistics returned. Q 2 is the predictivity of the model after the
(2.10)
potential effects of redundancy have been removed, sSDEP is the scaled SDEP.
the instantaneous slope of the predictivity with respect to the degree of perturbation. This
slope is the critical statistic. QSAR models which are unstable, i.e. models which change
greatly with small changes in underlying response values, are characterized by slopes
greater than 1.20. 60 Stable models, i.e. models which change proportionally with small
changes in underlying data, have slopes near unity.
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b. External Validation: In external validation, the models developed using the
compounds of the training set are used to predict the activity of the compounds in the test
set. The following statistical characteristics of the test set can be used to study the
stability and robustness of the model:59' 61
i) R2, correlation coefficient between the predicted and observed activities
ii) R, coefficient of determination between predicted versus observed
activities and Roe , coefficient of determination between observed versus
predicted activities
iii)	 Slopes k and k' of the regression lines through the origin.







The CnMFA QSAR equation can be depicted as 3D contour maps. Here it is worthwhile
to note that CoMFA contour maps do not show the commonality of all molecules but
rather map the relationship between structural differences and differences in biological
activity.5 1 This type of map helps to identify the steric and electrostatic features beneficial
to improved biological activity and also shows features which are detrimental to the
biological activity. Figure 2.3 shows an example. Regions of favorable steric interactions
for biological activity are shown in green, with sterically unfavorable regions in yellow.
Red contours show regions where increasing the positive charge at that location on the
ligand are correlated with decreased biological activity; blue contours indicate areas
where increasing the positive charge on the ligand are correlated with improved
biological activity. These maps can be used to suggest new molecules with increased
biological activity.
Figure 2.3 CoMFA contour maps.




All calculations were carried out on Silicon Graphics Origin 2000 workstations at New
Jersey Institute of Technology using the SYBYL molecular modeling program version
7.2. 62
3.2 Series of Analogs
Α series of salvinorin Α analogs with 2-position substituents were selected for the study
(Table 1.1). Biological activity was represented as ρΚ 1 , where pΚ; = -log Κ;, and Κ ; is the
binding affinity of the analog at the KOR. The series has a biological activity range
spanning 3 log units, an important condition for a reasonable 3D-QSΑR analysis. The
series was divided into a training set of twenty-six compounds and a test set (marked by
asterisks) of seven compounds. It is generally recommended 61 that the test set include no
fewer than five compounds. Compounds in the test set were selected to be representative
of the range of biological activity of the training set. All the analogs listed in Table 1.1
were created based on the crystal structure of salvinorin Α (Cambridge Crystal Database
code: DΑDΜΟΚ). 63 The geometry of the crystal structure was optimized using the
Powe1164 method of minimization, the Tripos force field65 and Gasteiger-Ηϋckel
charges. 66 Different side chains were added to this template structure at the 2-position and
the geometry of the resulting analogs was optimized and stored in a database. The
analogs were aligned using the standard database alignment option of SYBYL. The
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extended 2-butanοate analog, 4, was selected as the template for alignment. Before
performing alignment, 4 was oriented using the SYBYL command "ORIENT
BEST_VIEW". The "heavy" (non-hydrogen) atoms of the rings and oxygen of the 2-
position substituents were selected as the common substructure for alignment. As
described in Chapter 2, the steric and electrostatic interaction energies of each atom in the
analog with a probe atom (sp a carbon with charge 1) placed at different points on a grid
surrounding the molecule were calculated.
3.3 Preliminary and Focused CoMFA Models
The database of aligned molecules was used to create the molecular spreadsheets (MS).
The rows of the spreadsheet contain the analogs while the columns contain the biological
activity data (ρΚ1) and the steric and electrostatic interaction energies. The latter are
refered to as CoMFA columns with field class Tripos Standard. Separate CoMFA
columns were constructed with interaction energies from nine different steric
field/electrostatic field cutoffs (in units of kcal/mol): 60/1, 30/1, 10/1, 60/10, 30/10,
10/10; 60/30, 30/30 (default) and 10/30, with all other CoMFA parameters set to default.
Details of CoMFA input parameters are listed in Appendix A. Then the seven compounds
of the test set were "hidden" in each MS and the partial least square (PLS) with leave-
one-out (LOO)/cross-validation(CV) method using SAMPLS 67 was performed on the
twenty-six compounds of the training set. The initial number of components for the
LOO/CV method was set to six (default). The cross-validated model provided q 2
(predictivity) and standard error of prediction (SEP) for each component. The
steric/electrostatic cutoff of 30/1 kcal/mol gave the best q 2 and the data in the
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corresponding MS was used to develop the preliminary model. The optimum number
components was selected based on the lowest SEP, which generally corresponded to the
highest q2 or a value greater than 0.5, and was used to create the non-cross-validated
(NCV), or preliminary, model. The NCV model gave r2 (goodness of fit), standard error
of estimate (SEE), and the percent contribution of the steric and electrostatic fields.
The preliminary model was refined using Region Focusing,57 an iterative
procedure which increases the weight of those lattice points which are most relevant to
the model. This enhances the resolution and predictive power (q 2) of a subsequent PLS
analysis. StDev*Coefficient, the product of the variation at each lattice point with the
lattice point's regression coefficient from the model, and Discriminant Power, that
fraction of the variation in the model's components attributable to each lattice point, were
used as weights. Exponential factors of 0.3 (default), 0.5 and 1, recommended by Tripos
Bookshelf 7.2,68 were applied to each weight, and CoMFA calculations were carried out
using the 30/1 kcal/mol steric/electrostatic cutoff, giving a total of six focused models.
The LOO/CV model with the lowest SEP (and highest q2) in both the StDev*Coefficient
and Discriminant Power cases was used to construct the focused NCV (full) model for
each case. Both the focused NCV StDev*Coefficient and Discriminant Power models
were subjected to validation testing as described in the next section.
To study hydrogen-bonding behavior, the H-bond field class was used with a
probe atom type of H (charge 1) and a probe atom 0.3 (i.e. sp3 oxygen; charge -1). This
was done after setting the "TAILOR SET COMFA SWITCH_FCN" setting to "NO".
However, it was observed that adding the H-bond CoMFA field class gave models with
decreased values of q2 compared to those obtained with Tripos Standard CoMFA field
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class calculations described above. For this reason further calculations with the H-bond
field were not pursued.
Internal and External Validation In addition to the internal validation method of CV,
progressive scrambling (or y-value scrambling) 60 tests were performed on the focused
NCV StDev*Coefficient and Discriminant Power models. This estimates the stability of
the model with respect to random noise in the data. The y-value is the biological activity
(here, pKi at the KOR). This was done using 100 y-value scramblings with critical point
of 0.85, maximum number of bins equal to 8 and minimum number of bins equal to 2.
For the sake of reproducibility, the random seed was always chosen as "12345". All other
parameters were set to default values. All other details including key statistics are
explained in section 2.3.2. Based on the key statistics, the focused NCV
StDev*Coefficient and Discriminant Power models were identified either as stable or
unstable. As will be seen in the Results section, both models were found to be stable and
were used for external validation by predicting the biological activities of the compounds
in the test set using the test set correlation method as explained in the section 2.3.2. As
will be seen in the Results section, only the focused NCV Discriminant Power model
(with exponential factor 1) was found to be both stable and predictive. This model was
used to predict the biological activity of novel compounds.
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3.4 Novel Compounds
A 3D CoMFA contour map was created for the focused NCV Discriminant Power model
(with exponential factor 1) and used to identify key locations in 3D space where changing
steric and electrostatic characteristics would have an effect on the biological activity.
Salvinorin A was used as a template for interpreting the contour maps. The Optimize
QSAR procedure of SYBYL was used to replace selected hydrogen atoms with different
substituents, their geometry was optimized, and the biological activity of the modified
analogs was predicted. Those with the best biological activity (highest pΚ;) were




The butanoate analog used as a template for the database alignment is shown in Figure
4.1a. The alignment of all the test and training set analogs is shown in Figure 4.1b. Since
the structure of the analogs the same except for the 2-position, only that region shows
variation.
Figure 4.1 Alignment of salvinorin A analogs. a) Butanoate analog used as template
shown with hydrogens, b) Aligned salvinorin A analogs shown without hydrogens
for clarity
4.2 Preliminary and Focused Models; Internal Validation
The results of the NCV PLS preliminary model and the associated LOO/CV PLS model
based on the steric/electrostatic cutoff of 30/1 kcal/mol are summarized in Table 4.1,
along with the LOO/CV model for the default steric/electrostatic cutoff (30/30kca1/mol),
given for comparison purposes only. Compared to the results obtained with the default
cutoff, q2 increased to 0.408 from 0.255 (15%) and SEP decreased to 0.670 from 0.769.
79
80
cutoff, q2 increased to 0.408 from 0.255 (15%) and SEP decreased to 0.670 from 0.769.
Although the q2 value of 0.408 is below the widely-accepted value of 0.561,68,69 for a
predictive CoMFA model, it is άbove the statistical 95% confidence limit of q 2 = 0.3. 70
Results of the LOO/CV models with other steric field/electrostatic field cutoffs (in units
of kcal/mol: 60/1, 10/1, 60/10, 30/10, 10/10; 60/30, 30/30 and 10/30) are listed in
Appendix B.
Table 4.1 Preliminary Results of the QSAR Study on Salvinorin A Analogs
The LOO/CV focused models developed using different weights and exponential
factors are summarized in Table 4.2. The highest q 2 and lowest SEP in the
StDev*Coefficient case (q 2 = 0.529; SEP = 0.612) occur for exponential factor 0.5; the
highest q2 and lowest SEP in the Discriminant Power case (q 2 = 0.621; SEP = 0.549)
occur for exponential factor 1. NCV PLS (full) models were only developed for these
two cases. As shown in Table 4.3, the r2 and percent steric and electrostatic contribution
for both these focused NCV models is similar. The Progressive Scrambling results are
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also summarized in Table 4.3. The stability tests show that both models are robust and
2 '
stable based on Q2, cSDEP and dq . 2  values are expected to be more conservativern,,
than LOO/CV q2 values and even a Q 2 value as low as 0.35 signifies that the original,
unperturbed model is robust. 68 Since the focused NCV StDev*Coefficient and
Discriminant Power models have Q 2 equal to 0.416 and 0.498, respectively, they are
robust. The cross-validated standard deviation of error of prediction (cSDEP) values are
similar to SEP values obtained from the original, unperturbed models. The value of
for both models is below 1.2 and also signifies stability. 60
Based on these results, both models in Table 4.3 were selected as acceptable
models and used to predict the pK;s of the compounds in the training set. Predictions from
the models are compared to experimental values in Figure 4.2. The training set analogs
are spread out uniformly around the ideal diagonal line for both the models. The training
set predictions and residual values (predicted pΚί - experimental ρΚ 1) obtained from both
models are listed in Appendix C and are generally small. For the focused NCV
StDev*Coefficient and Discriminant Power models, the average and minimum residuals
for the training set are 0 and -0.67, respectively; the average absolute value of the errors
are 0.26 and 0.25, respectively; and the maximum residuals are 0.64 and 0.55,
respectively.
Table 4.2 Focused LOO/CV Models of the QSAR Study on Salvinorin A Analogs
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Figure 4.2 Training set predictions of the QSAR study of salvinorin A analogs.
(a) Model based on StDev*Coefficient as weights and exponential factor of 0.5, (b)
Model based on Discriminant Power as weights and exponential factor of 1.
4.3 External Validation: Prediction of Activity of Test Set Analogs
Since both models are stable, both were used to predict the ρΚis of the compounds in the
test set. For the focused NCV StDev*Coefficient and Discriminant Power models, the
average absolute residuals were 0.53 and 0.54, respectively; the minimum residuals were
-0.91 and -1.14, respectively; and the maximum residuals were 0.61 and 0.22,
respectively. The test set predictions and residual values (predicted pHi - experimental
ρHi) obtained from both models are listed in Appendix C. The test set predictions were
used to validate the models as recommended by Tropsha et a1. 61 '69 The recommended
key characteristics of the test set useful to identify a predictive model are listed in Table
4.4 and plots are shown in Figure 4.3. From the values in the table and plots it is clear
that only the focused NCV Discriminant Power model (exponential factor 1) is a stable
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and predictive model. It satisfies all the characteristics of a predictive model listed in the
CoMFA background section of 2.3.2. The most notable characteristic is the R2 value of
0.665, which is greater than 0.6 and is closer to the R' 02 value of 0.650. This value is close
to the cross-validated R2 (q2) value of 0.621 obtained from the respective LOO/CV
model. This model was used to create the CoMFA contour map and to predict the
activities of novel compounds as explained in the next section.
a Correlation coefficient between the predicted pKi and experimental pK i
Coefficient of determination for the zero-intercept line of predicted pK i vs.
experimental pKi
Slope of the zero-intercept line of predicted vs. experimental pK i
d Coefficient of determination for the zero-intercept line of predicted pK i vs.
experimental ρKi
e Coefficient of determination for the zero-intercept line of experimental pKi vs.
predicted pKi
Maximum of the coefficients of determination for the zero-intercept lines
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Figure 4.3 Test set predictions of the QSAR Study on salvinorin A analogs. Best-fit
line with R2 and zero-intercept line with Roe for predicted ρΚi vs. experimental pΚ i
and R' 02 for experimental pΚi vs. predicted pΚ i , (a) and (b) Model based
StDev*Coefficient as weights and exponential factor of 0.5, (c) and (d) Model based
on Discriminant Power as weights and exponential factor of 1.
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4.4 Novel Compounds
The CoMFA steric/electrostatic contour map for the focused NCV Discriminant Power
model is shown in Figure 4.4a with the parent salvinorin A molecule as a reference. In
general, the map indicates that increasing the steric bulk near the green areas and
decreasing the steric bulk near the yellow areas would lead to a higher pΚI, as would
increasing the positive charge near blue areas and increasing the negative charge near the
red areas. Specific areas of interest are the green region near the carbonyl carbon, where
an increase in bulk would improve ρΚ 1, and the red region near the methyl group where
an increase in the negative charge would lead to a higher pΚ I , as shown schematically in
Figure 4.4b. The other area of interest is the blue region where an increase in positive
charge may improve pΚI. The contour map also indicates that steric and electrostatic
fields both play an important role in activity.
Based on the above observations, the QSAR Optimization tool of SYBYL was
used to find the optimal substitution pattern at Xi, Χ2, and Χ3 (Figure 4.4b) and to get an
idea of the range of activities expected by changing substituents. The complete list of
substituents used to make Χ1, Χ2, and Χ3 combinations along with the QSAR
Optimization settings is included in Appendix D. Not all combinations gave improved
pΚI values. Only the twenty compounds with pΚ I greater than 8 are shown in Table 4.5.
The complete results are given in Appendix E. These were suggested to Dr. Thomas
Prisinzano of the University of Iowa for synthesis. Out of these twenty analogs,
preliminary biological results for 2, 3 and 8 are available from the Rothman laboratory at
the National Institute on Drug Abuse. All three analogs appear to be KOR selective.
Preliminary biological tests were conducted on human μ, δ and κ opioid receptors
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expressed in Chinese Hamster Ovary Cells (CHO cells) using { 1251]IΟΧΥ as a
radioligand. 71 Currently binding studies are underway in the Rothman laboratory and we
are awaiting the binding affinity data.
Figure 4.4 (a) Results of CoMFA steric/electrostatic contour maps with salvinorin A
as reference, (b) Prescription for changes in regions of interest, shown schematically.




The 3D-QSAR study performed on 2-position salvinorin A analogs highlighted important
characteristics required for the better binding affinity (expressed in terms of ρΚ1) at the
KOR. The study showed that both steric (47%) and electrostatic properties (53%)
contribute almost equally to the model and hence to the binding affinity. The study
showed the importance of trying a range of steric and electrostatic cutoff values in order
to optimize the preliminary models.
The 3D-QSAR study performed here further reinforced the fact that both y-value
scrambling and test set correlation validation should be applied to evaluate the
predictivity of the model. This should be done in addition to the criteria of q 2 > 0.5.61 6972
The most important part of QSAR model development is the model validation.
Performing just leave-one-out (or leave-some-out) cross-validation procedure is not
sufficient to evaluate the predictivity of the model. The condition that a test set should
have at least five compounds may be problematic for a small set of compounds
(for example the present data set with less than 35 compounds), nevertheless an external
test set should be used to gauge the predictivity of the model. Using recommended
validation measures allowed the development of a stable and predictive model which was
used to predict the binding affinity of the novel analogs. Initial biological results show
promise but a definitive picture will appear only after the binding affinity data of novel
analogs becomes available.
The observation that adding the H-bond CoMFA field class gave models with
decreased values of q2 compared to those obtained with Tripos Standard CoMFA field
class calculations is an interesting point to note. It suggests that for the 2-position
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salvinorin A analogs, hydrogen bonding may not play a role in explaining their observed
biological activity. This possibility was also suggested based on mutagenesis studies of
Tyr313 residue of KOR which is proposed to interact with 2-position of salvinorin A.
Mutating to Tyr313 to Phe resulted in no loss of binding affinity,29 while mutating it to
Ala gave a dramatic decrease in affinity. However, the final CoMFA model suggests the
role of electrostatic properties in addition to steric properties. There is a possibility that
electrostatic interactions other than hydrogen bonding might play a role in binding of 2-
position of salvinorin A analogs at the KOR.
It is known that salvinorin A is metabolized to an inactive form of salvinorin B
which has a hydroxyl group at position 2. 73°74 There is also a difference in the observed
in-vivo and in-vitro activity of salvinorin A probably due to the same reason. Because of
the presence of the electronegative fluorine (a good leaving grοup), 75 it remains to be
seen whether the fluorinated analogs of Table 4.5 are metabolized at the same rate or
more rapidly than the parent salvinorin A. It will be interesting to compare the results of




The 3D-QSAR method of CoMFA, based on ligands (in present study: salvinorin A
analogs) can be applied in absence of a reliable structure of the receptor (in present study:
κΟR) to obtain a predictive and stable model using internal (LOO/CV and y-value
scrambling) and external validation (test set correlation validation) tools. The ligand-
based approach applied here is specifically valuable because proposed binding models of
salvinorin A with the κΟR based on homology modeling of proteins with mutagenesis
data have not been able to provide a clear picture of the molecular properties playing role
in the binding.
Figure A.1 Local minima of 2 and 3 in (Β2, Β3) space. Torsional angles are given in
degrees. Minima are color coded by energy in units of kcal/mol. GEM marked by circle. Plot




Figure Α.2 Local minima of 2 and 3 in (Β3, Β4) space. Legend same as Figure Al.
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Figure A3 Local minima of 2 and 3 in (Β4, B6) space. Legend same as Figure Al. The GEM
structure appears twice due to the symmetry of the molecule to rotation of the phenyl ring
around the Β6 torsional angle.
Figure A.4 Local minima of 2 and 3 in (Β5, Β6) space. Legend same as Figure Al. The GEM
structure appears four times due to the symmetry of the molecule to rotation of the phenyl ring
around the Β5 and Β6 torsional angles.
95
Part II- APPENDIX A
COMFA INPUT PARAMETERS
SYBYL CoMFA Parameters
All settings were kept as default except for changes in steric and electrostatic cutoffs.
CoMFA Field Class: Tripos Standard
Field Values: Type(s): Both
Dielectric: Distance
Smoothing: None





Column to Use: CoMFA Field, pΚ;
Dependent Column: pΚ;
Validation: "Leave-One-Out" box checked
"Use SAMPLS" box checked
Components: 6
Scaling: CoMFA Standard
NCV Full Model 
Column to Use: CoMFA Field, pΚi
Dependent Column: pΚI
Validation: "No Validation" box checked
Components: Selected based on LOO/CV
Scaling: CoMFA Standard
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PART II- APPENDIX B
PRELIMINARY COMFA MODELS - COMBINATIONS OF STERIC AND
ELECTROSTATIC CUTOFFS
Table B.1 Preliminary LOO/CV Results of the QSAR Study on Salvinorin A Analogs
LOO/CV PLS




























a Optimal number of components selected from LOO/CV model
b Standard error of prediction
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PART II- APPENDIX C
RESIDUALS
Table C.1 Training Set and Test Set (shown with asterisks) Predictions
Model 1
Weights = StDev*Coefficient
Exponential factor = 0.5
Model 2
Weights = Discriminant Power








-0.301 8.72 8.32 -0.40 8.42
2 8.74 8.17 -0.57 8.07 -0.67
3 7.72 7.91 0.19 7.88 0.16
4* 8.40 7.49 -0.91 7.26 -1.14
5* 7.82 7.46 -0.37 7.22 -0.60
6 7.15 7.19 0.04 6.94 -0.21
7 6.37 6.35 -0.02 5.95 -0.42
8 7.05 6.38 -0.67 6.52 -0.53
9* 7.05 6.71 -0.34 6.79 -0.26
10 7.15 6.52 -0.63 6.59 -0.56
11 6.13 5.90 -0.23 5.79 -0.34
12 5.71 5.80 0.09 5.64 -0.07
13* 6.54 7.15 0.61 6.76 0.22
14 6.74 7.38 0.64 7.10 0.36
15 6.59 6.99 0.40 6.77 0.18
16 7.03 7.27 0.24 7.38 0.35
17 6.92 7.05 0.13 7.30 0.38
18* 7.05 7.37 0.32 6.90 -0.15
19* 7.19 6.70 -0.49 6.14 -1.05
20 7.38 7.60 0.22 7.90 0.52
21 6.64 6.53 -0.11 6.64 0.00
22 6.26 6.27 0.01 6.41 0.15
23 6.27 6.20 -0.07 6.30 0.03
24 6.49 6.76 0.27 6.77 0.28
25 6.49 6.80 0.31 6.58 0.09
26 6.39 6.39 0.00 6.40 0.01
27 5.26 5.61 0.35 5.81 0.55
28 7.15 6.77 -0.38 7.06 -0.09
29 7.10 7.06 -0.04 6.79 -0.31
30* 5.70 6.16 0.46 5.70 0.00
31 5.68 6.08 0.40 5.73 0.05
32 6.19 5.63 -0.56 6.21 0.02
33 5.50 5.54 0.04 5.62 0.12
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PART II- APPENDIX D
QSAR OPTIMIZATION
Table D.1 Substituents Used for Various Χ1, Χ2, and Χ3 Combinations (Figure 4.3b) for
QSAR Optimization
-Η (Default) -OH - CF3 -NO2
-F -OCH3 -CF2H -CONH2
-Cl -CN - CH2F -CONHCH3
-Br -NH2 -CH2C1
-CH3 -NHCH3 -COOH
D.2 QSAR Optimization Settings
Source Table <name of the molecular spreadsheet>
Configuration Option
Conformation Refinement: Relax
Computation of Charges: GAST_HUCK
Analysis <name of the PLS analysis>	 Optimize: PΚi
Core Molecule <Ml> New Area<M2>	 Work Area<M3>
Method = Linear
Best = 250
Run Name <name of the run>
Default Substituent Table <name of the table with substituents>
Assign R Groups <assign appropriate R groups from the substituents table>
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PART II- APPENDIX E
PREDICTION OF NOVEL ANALOGS
Table E.1 Prediction of novel analogs using Optimized QSAR based on Focused Model
with Weights = Discriminant Power, Exponential factor = 1
Novel Analogs Predicted ρεI Χ1 Χ2 Χ3
1 8.64F Η Cl
2 8.57 F Η F
3 8.56 F Η Br
4 8.5 F Η Η
5 8.5 F Η Η
6 8.49 F Η Η
7 8.46 ΟΗ Η Η
8 8.460Η Η Η
9 8.45 ΝΗ2 Η Η
10 8.44 F Η CN
11 8.44 ΝΗ2 Η Η
12 8.42 Η Η Η
13 8.42 Η Η Η
14 8.42 Η Η Η
15 8.42 Η Η Η
16 8.42 Η Η Η
17 8.41C1 Η Η
18 8.41 C1 Η Η
19 8.38 Η Η Br
20 8.37 Br Η Η
21 8.37Br Η Η
22 8.34 F Η CO2H
23 8.32 Η Η Cl
24 8.32 CN Η Η
25 8.32 CN Η Η
26 8.28 F Η ΟΗ
27 8.27 F Η OMe
28 8.25 F Η CF3
29 8.25 Methyl Η Η
30 8.24 Methyl Η Η
31 8.2 F Methyl Η
32 8.19F Η Methyl
33 8.19F Η NHMe
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34 8.16 Η Η Methyl
35 8.15F Η ΝΟ2
36 8.14F Η ΝΗ2
37 8.12 CF3 Η Η
38 8.12 Η Methyl Η
39 8.12 CF3 Η Η
40 8.11 F Η CH2C1
41 8.08 Η ΝΗ2 Η
42 8.06 Η Η F
43 8.02 Η Η CH2C1
44 7.98 Η Η ΟΗ
45 7.96 Η Η CF3
46 7.94 Η Η OMe
47 7.92 Η Η CH2F
48 7.89 F Br Η
49 7.88F ΟΗ Η
50 7.87 Η Η NHMe
51 7.85 F CO2H Η
52 7.85 Η Η CN
53 7.84 F Η CH2F
54 7.84 Η Η ΝΗ2
55 7.83 CF2H Η Η
56 7.81 Η Η CONH2
57 7.81 Η Η CONHMe
58 7.79 F Η CF2H
59 7.79 F Cl Η
60 7.76 CF2H Η Η
61 7.63 Η Η ΝΟ2
62 7.62 F CH2C1 Η
63 7.6 Η CO2H Η
64 7.59 Η ΟΗ Η
65 7.58 CO2H Η Η
66 7.57 F ΝΗ2 Η
67 7.56 CO2H Η Η
68 7.55 Η Br Η
69 7.48 F NHMe Η
70 7.47 Η CH2CL Η
71 7.43 Η Cl Η
72 7.41 F CF2H Η
73 7.41 CONH2 Η Η
74 7.4 Η Η CF2H
75 7.4 F CH2F Η
76 7.35 CH2F Η Η
77 7.35F F Η
78 7.35 CH2F Η Η
79 7.32 Η CH2F Η
80 7.29 Η CONH2 Η
81 7.29 Η NHMe Η
82 7.28 Η CF2H Η
83 7.24 F Η CONHMe











87 7.18F OMe Η
88 7.11 Η CONHMe Η _
89 7.09 F CF3 Η
90, 7.04 CONHMe Η Η
91 7.02 NHMe Η Η
92 7.02 01Μ Η Η
93 7.02 F CN Η
94 6.97Η F Η
95 6.86 NHMe Η Η
96 6.84 Η OMe Η
97 6.66 F CONHMe Η
98 δ.63 Η CN Η
99 δ.59 Η CF3 Η
100 6.5 CH2Cl Η Η
101 6.48 CH2Cl Η Η
102 6.44 CONH2 Η Η
103 6.44 CONHMe Η Η
104 6.33 F ΝΟ2 Η
105 6.3 F CONH2 Η
106 δ.24 ΝΟ2 Η Η
107 6.02 Η 	 ΝΟ2 Η
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